var title_f18_3_18480="Anterior view superficial veins of the upper extremity";
var content_f18_3_18480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior view superficial veins of the upper extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <ul>",
"     <li>",
"      The cephalic vein originates at the radial aspect of the wrist traversing the radial border of the forearm. It receives tributaries from both the ventral and dorsal surfaces. At the antecubital fossa it provides a tributary to the median cubital vein. In the upper arm, it travels in the groove between the pectoralis major and deltoid muscles. It pierces the coracoclavicular fascia and, crossing the axillary artery, ends in the axillary vein just below the clavicle. Sometimes it communicates with the external jugular vein by a branch which ascends anterior to the clavicle.",
"     </li>",
"     <li>",
"      The basilic vein originates in the ulnar aspect of the wrist traversing the ulnar side of the forearm to the antecubital fossa where it is joined by the median cubital vein. It ascends in the groove between the biceps brachii and pronator teres, crosses the brachial artery at the elbow and continues cephalad along the medial border of the biceps brachii. It perforates the deep fascia of the upper arm and joins the brachial vein.",
"     </li>",
"    </ul>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18480=[""].join("\n");
var outline_f18_3_18480=null;
var title_f18_3_18481="Variations in the origin and course of the cystic artery";
var content_f18_3_18481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Variations in the origin and course of the cystic artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Variation in the origin and course of the cystic artery. The cystic artery usually arises from the right hepatic artery. Variations in the origin and course of the cystic artery occur about 25 percent of people",
"    <sup>",
"     [1,2]",
"    </sup>",
"    , which is of clinical significance during surgical removal of the gallbladder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Anson BJ. Anatomical considerations in surgery of the gallbladder. Q Bull Northwest Univ Med Sch. 1956; 30:250.",
"      </li>",
"      <li>",
"       Michel NA. The hepatic, cystic and retroduodenal arteries and their relations to the biliary ducts with samples of the entire celiacal blood supply. Ann Surg 1951; 133:503.",
"      </li>",
"     </ol>",
"     <br/>",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18481=[""].join("\n");
var outline_f18_3_18481=null;
var title_f18_3_18482="Patient information: Dementia with Lewy bodies (The Basics)";
var content_f18_3_18482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/20/2370\">",
"         Patient information: Mild cognitive impairment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/40/13954\">",
"         Patient information: Parkinson disease (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/37/14934\">",
"         Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/4/5188\">",
"         Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dementia with Lewy bodies (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dementia-with-lewy-bodies-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15630505\">",
"      <span class=\"h1\">",
"       What is dementia with Lewy bodies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dementia with Lewy bodies is 1 of a group of brain disorders called &ldquo;dementia.&rdquo; This group of brain disorders causes memory problems and makes it hard to think clearly.",
"     </p>",
"     <p>",
"      The cause of dementia with Lewy bodies (called &ldquo;DLB&rdquo; here) is not known. There are changes in the brains of people with DLB. The changes are called Lewy bodies.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15630520\">",
"      <span class=\"h1\">",
"       What are the symptoms of DLB?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems making decisions, thinking clearly, or paying attention. These can include:",
"       </li>",
"       <li>",
"        Problems driving &ndash; A person with DLB might get lost, not know how far it is from 1 place to another, or not see other cars.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Problems at work",
"       </li>",
"       <li>",
"        Memory problems",
"       </li>",
"       <li>",
"        A shorter attention span than normal",
"       </li>",
"       <li>",
"        Problems figuring out how to do normal daily activities",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Seeing things that are not really there &ndash; Doctors call these &ldquo;hallucinations.&rdquo; They can include colors, shapes, animals, or people.",
"       </li>",
"       <li>",
"        Being sleepy, staring at things, or acting strangely - The person might take long naps during the day. The times of being sleepy, staring, or acting strangely can last a few minutes or several days.",
"       </li>",
"       <li>",
"        Movement problems - These can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Stiffness",
"       </li>",
"       <li>",
"        Slow movements",
"       </li>",
"       <li>",
"        Trouble walking",
"       </li>",
"       <li>",
"        Trembling",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other DLB symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Acting out dreams while sleeping &ndash; The person might hit someone, eat, talk, or do other things they are dreaming about. &nbsp;",
"       </li>",
"       <li>",
"        Falling down often",
"       </li>",
"       <li>",
"        Fainting or losing consciousness",
"       </li>",
"       <li>",
"        Leaking urine",
"       </li>",
"       <li>",
"        Believing things that are not true &ndash; For example, a person with DLB might believe his or her house is not really home.",
"       </li>",
"       <li>",
"        Depression",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15630535\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You should see a doctor or nurse if you think you or someone close to you shows signs of DLB. The problems might be caused by a different condition that doctors can treat. For example, people with diabetes might act confused if their blood sugar is not under control. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15630550\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will do an exam and talk with you about your symptoms. He or she will also ask people who are close to you about any symptoms they notice.",
"     </p>",
"     <p>",
"      Your doctor or nurse might do tests to see if you have DLB or a different problem. These tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Answering questions and doing certain tasks &ndash; These tests can tell the doctor how well your brain is working.",
"       </li>",
"       <li>",
"        Imaging tests, such as an MRI &ndash; An MRI creates pictures of the brain. It can show changes in the brain, including other conditions that could be causing symptoms.",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on the results, you might have other tests. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A test called an &ldquo;electroencephalogram&rdquo; (also called an EEG) &ndash; This test measures electrical activity in the brain.",
"       </li>",
"       <li>",
"        A test called a &ldquo;sleep study&rdquo; &ndash; In this test, you spend the night in a lab at the hospital or doctor&rsquo;s office. You are hooked up to machines that measure your heart rate, breathing, and other body functions. The results tell your doctor more about any sleep problems you have.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15630567\">",
"      <span class=\"h1\">",
"       How is DLB treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no specific treatment for DLB. The symptoms get worse over time, but doctors can help treat the symptoms. Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to help with symptoms",
"       </li>",
"       <li>",
"        Physical therapy to help with movement problems",
"       </li>",
"       <li>",
"        Devices, such as a walker or cane, to help with balance problems such as falling down often.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor might also recommend things to reduce stress. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Exercise",
"       </li>",
"       <li>",
"        A regular routine &ndash; Avoiding things that cause confusion or strange behavior can help with DLB. Having a regular routine at night can be especially helpful.",
"       </li>",
"       <li>",
"        Spending time with pets or listening to music",
"       </li>",
"       <li>",
"        Finding someone to help take care of the person with DLB &ndash; This can make it easier for the person&rsquo;s main caregiver, such as his or her husband or wife, to get enough rest.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15630582\">",
"      <span class=\"h1\">",
"       How do I stay safe?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have DLB, you might not realize how much it affects you. Trust your family and friends to tell you when it is not safe for you to drive, cook, or do other things that could be dangerous.",
"     </p>",
"     <p>",
"      People with DLB often fall and hurt themselves. To reduce the risk of falling, it is a good idea to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Make sure your rugs are attached to the floor, or use non-skid backing on them.",
"       </li>",
"       <li>",
"        Tuck away loose wires or electrical cords.",
"       </li>",
"       <li>",
"        Wear sturdy, comfortable shoes.",
"       </li>",
"       <li>",
"        Keep walkways well lit.",
"       </li>",
"       <li>",
"        Use hand rails on steps, in the shower, and other places where it can be hard to keep your balance.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15630599\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=see_link\">",
"       Patient information: Mild cognitive impairment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=see_link\">",
"       Patient information: Parkinson disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=see_link\">",
"       Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/3/18482?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83158 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18482=[""].join("\n");
var outline_f18_3_18482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15630505\">",
"      What is dementia with Lewy bodies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15630520\">",
"      What are the symptoms of DLB?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15630535\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15630550\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15630567\">",
"      How is DLB treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15630582\">",
"      How do I stay safe?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15630599\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=related_link\">",
"      Patient information: Mild cognitive impairment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=related_link\">",
"      Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_3_18483="Color flow Doppler MR I";
var content_f18_3_18483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color flow Doppler of mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows an apical four chamber view with color flow Doppler of mild mitral regurgitation (MR); mild tricuspid regurgitation (TR) is also present. The regurgitant jets have a mosaic of color because their high velocities are represented by an aliased signal; they begin with a very narrow point of origin at the valve, remain narrow and penetrate only partially into the left atrial (LA) cavity. These are characteristics of mild regurgitant lesions. In panel B, the size of the MR jet at the site of origin is wider, the jet reaches the posterior LA wall, and blood begins to accelerate before reaching the valve; these are characteristics of moderate to severe MR. In panel C, the jet is even wider, almost filling the LA, and it reaches the posterior LA wall and enters the pulmonary veins. Panel D is from a patient with rheumatic MR and a giant LA; proper gain settings show marked spontaneous echo contrast (D1). With slightly lower gain setting spontaneous echo contrast is artifactually not seen (D2). Panel D3 shows a narrow jet of trivial mitral regurgitation (MR); spontaneous echo contrast does not develop when MR is moderate or severe.",
"    <div class=\"footnotes\">",
"     RA and LA: right and left atria; LV and RV: left and right ventricles.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18483=[""].join("\n");
var outline_f18_3_18483=null;
var title_f18_3_18484="Pilocarpine (ophthalmic): Patient drug information";
var content_f18_3_18484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pilocarpine (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4548?source=see_link\">",
"     see \"Pilocarpine (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/40/25219?source=see_link\">",
"     see \"Pilocarpine (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isopto&reg; Carpine;",
"     </li>",
"     <li>",
"      Pilopine HS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diocarpine;",
"     </li>",
"     <li>",
"      Isopto&reg; Carpine;",
"     </li>",
"     <li>",
"      Pilopine HS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pilocarpine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697992",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lowered night eyesight. Use care when driving or doing other tasks that call for clear eyesight. Keep work space well lit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705555",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place drug inside the lower lid. Close the eye for 1 to 2 minutes. Roll eyeball around.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12289 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18484=[""].join("\n");
var outline_f18_3_18484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505057\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505058\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024542\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024541\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024546\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024547\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024549\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024544\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024545\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024550\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024551\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4548?source=related_link\">",
"      Pilocarpine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/40/25219?source=related_link\">",
"      Pilocarpine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=related_link\">",
"      Pilocarpine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/52/28484?source=related_link\">",
"      Pilocarpine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7876?source=related_link\">",
"      Pilocarpine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_3_18485="Anastrozole: Patient drug information";
var content_f18_3_18485=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Anastrozole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     see \"Anastrozole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arimidex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Anastrozole&reg;;",
"     </li>",
"     <li>",
"      Arimidex&reg;;",
"     </li>",
"     <li>",
"      JAMP-Anastrozole;",
"     </li>",
"     <li>",
"      Mar-Anastrozole;",
"     </li>",
"     <li>",
"      PMS-Anastrozole;",
"     </li>",
"     <li>",
"      Riva-Anastrozole;",
"     </li>",
"     <li>",
"      Sandoz-Anastrozole;",
"     </li>",
"     <li>",
"      Taro-Anastrozole;",
"     </li>",
"     <li>",
"      Teva-Anastrozole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691764",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer in women after change of life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to anastrozole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703796",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not stopped your period.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or are taking a cholesterol-lowering drug, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698386",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10953 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18485=[""].join("\n");
var outline_f18_3_18485=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135534\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135535\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026621\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026623\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026622\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026627\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026628\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026630\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026625\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026626\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026631\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026632\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=related_link\">",
"      Anastrozole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_3_18486="Granulomatous hepatitis Light";
var content_f18_3_18486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Granulomatous hepatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a liver biopsy shows a noncaseating granuloma and perigranulomatous mononuclear cell inflammation with hepatic necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18486=[""].join("\n");
var outline_f18_3_18486=null;
var title_f18_3_18487="CDC weight for stature boys 2 to 5 years";
var content_f18_3_18487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55850%7EPEDS%2F65129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55850%7EPEDS%2F65129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Weight-for-stature percentiles for boys 2 to 5 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 680px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Weight-for-stature percentiles for girls 2 to 5 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 673px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18487=[""].join("\n");
var outline_f18_3_18487=null;
var title_f18_3_18488="Trichinella larvae in muscle";
var content_f18_3_18488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trichinella larvae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trichinella larvae are seen in an undigested muscle biopsy specimen compressed between microscope slides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Weller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18488=[""].join("\n");
var outline_f18_3_18488=null;
var title_f18_3_18489="Approach to the diagnosis of hemolytic anemia in the adult";
var content_f18_3_18489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the diagnosis of hemolytic anemia in the adult",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/3/18489/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/3/18489/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/3/18489/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/3/18489/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/3/18489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/3/18489/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/3/18489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemia is defined as anemia due to a shortened survival of circulating red blood cells (RBCs). Although the time of RBC senescent death in adults is 110 to 120 days, it is convenient to define hemolysis as a shortening of RBC survival to a value of less than 100 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=see_link\">",
"     \"Red blood cell survival: Normal values and measurement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will provide an introduction to the phenomenon of hemolysis and the tests that may be used to provide a diagnosis. A more general approach to the subject of anemia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RBC KINETICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Random hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the death of aging (senescent) RBCs, there is age-independent RBC destruction (random hemolysis) in normal subjects in the range of less than 0.05 to 0.5 percent per day. This latter process is appreciably increased in hemolytic states, especially when destruction in an enlarged spleen is part of the hemolytic process [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/1\">",
"     1",
"    </a>",
"    ]. When the rate of random hemolysis is sufficiently high, RBCs die solely from this process, since few survive long enough to die of senescence. As an example, when the rate of random hemolysis is 0.5 percent per day, the chance that a RBC will survive for at least 100 days is 61 percent; this value falls to less than 1 percent when the rate of random hemolysis reaches 5 percent per day.",
"   </p>",
"   <p>",
"    When hemolysis occurs, the degree of anemia is minimized by a compensatory increase in the secretion of erythropoietin (EPO), which enhances RBC production. This response is manifested initially by an increase in the reticulocyte percentage and absolute reticulocyte count, followed by an increase in hemoglobin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H38#H38\">",
"     \"Approach to the adult patient with anemia\", section on 'Reticulocyte count'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     RBC lifespan and turnover",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under steady state conditions, in which the secretion and response to erythropoietin are intact, RBC survival can be estimated from the reticulocyte percentage, the hematocrit, and the reticulocyte lifespan (RLS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=see_link\">",
"     \"Red blood cell survival: Normal values and measurement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &nbsp;RBC survival (days) &asymp; 100 &nbsp;&divide; &nbsp;[Reticulocytes (percent) &nbsp;&divide; &nbsp;RLS (days)]",
"   </p>",
"   <p>",
"    For this calculation, the RLS equals 1.0, 1.5, 2.0, or 2.5 days at hematocrits of 45, 35, 25, and 15 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef61552 \" href=\"UTD.htm?32/34/33325\">",
"     figure 1",
"    </a>",
"    ). The reason for this prolongation in RLS in the circulation is that, with worsening anemia and increased erythropoietin stimulation, reticulocytes leave the bone marrow at progressively earlier stages in their maturation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H38#H38\">",
"     \"Approach to the adult patient with anemia\", section on 'Reticulocyte count'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The RBC turnover rate, the reciprocal of RBC survival, equals:",
"   </p>",
"   <p>",
"    &nbsp;RBC turnover rate",
"    <span class=\"nowrap\">",
"     (percent/day)",
"    </span>",
"    &nbsp;= &nbsp;100 &nbsp;&divide; &nbsp;RBC survival (days)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical example: transient aplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical utility of this approach can be appreciated by a clinical example. An adult with sickle cell anemia has a hematocrit (HCT) of 27 percent and a reticulocyte count of 15 percent. Using the above formulae, the estimated RBC survival is 13 days (100 &divide; [15 &divide; 2]) and the rate of RBC turnover is 7.5",
"    <span class=\"nowrap\">",
"     percent/day",
"    </span>",
"    (100 &divide; 13).",
"   </p>",
"   <p>",
"    This turnover rate exceeds the adult marrow's maximum sustainable capacity (5",
"    <span class=\"nowrap\">",
"     percent/day",
"    </span>",
"    in adults; normal: 1",
"    <span class=\"nowrap\">",
"     percent/day).",
"    </span>",
"    Thus, this patient's marrow can only deliver 67 percent (5 &divide; 7.5) of the needed RBCs, resulting in a HCT of 27 percent (67 percent of the normal value of 40 percent). If this patient's bone marrow is suppressed, such as during an intercurrent infection, a lower HCT rapidly ensues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If, as an example, this subject's RBC production were virtually 100 percent suppressed, as may occur with parvovirus B19 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/3\">",
"     3",
"    </a>",
"    ], the rate of fall of the HCT will be 7.5 percent per day. After seven days of complete erythroid suppression, circulating RBCs will have fallen by 52.5 percent (7 x 7.5), to a HCT of 14 percent, with severe clinical consequences. By contrast, in a normal subject with a RBC turnover rate of 1",
"    <span class=\"nowrap\">",
"     percent/day,",
"    </span>",
"    seven days of complete erythroid suppression would result in a decrease in HCT of only 7 percent, which would not be clinically obvious. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RETICULOCYTE RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major finding in most patients with hemolytic anemia is an increase in the reticulocyte percentage and the absolute reticulocyte count. These findings reflect the bone marrow's response to anemia, as long as adequate iron and other nutrients are available, and are not specific for hemolysis, since a similar response occurs after acute blood loss.",
"   </p>",
"   <p>",
"    The normal reticulocyte percentage is 0.5 to 1.5 percent (",
"    <a class=\"graphic graphic_table graphicRef64238 \" href=\"UTD.htm?41/52/42827\">",
"     table 1",
"    </a>",
"    ). The increase in erythropoietin production induced by anemia should raise the reticulocyte percentage above 4 to 5 percent. In one series of patients with autoimmune hemolytic anemia, as an example, the median reticulocyte percentage at diagnosis was 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with lesser degrees of hemolysis do not become anemic unless the rate of hemolysis exceeds the ability of that patient's bone marrow to increase its red cell production by a similar amount (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Hemolysis without anemia'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Absolute reticulocyte count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of reticulocyte counting can be improved by determination of the absolute reticulocyte count [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The normal RBC count is",
"    <span class=\"nowrap\">",
"     5,000,000/microL",
"    </span>",
"    and the normal reticulocyte value is 1 &plusmn; 0.5 percent; accordingly, the normal absolute reticulocyte count ranges from 25,000 to",
"    <span class=\"nowrap\">",
"     75,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    value of this calculation can be appreciated from the following example. A severely anemic patient has a hematocrit of 18 percent, a RBC count of",
"    <span class=\"nowrap\">",
"     2,000,000/microL,",
"    </span>",
"    and a reticulocyte count of 3 percent. This patient may appear to have a reticulocytosis, given that the normal reticulocyte percentage is in the range of 0.5 to 1.5 percent. However, the absolute reticulocyte count is within the normal range",
"    <span class=\"nowrap\">",
"     (60,000/microL),",
"    </span>",
"    which represents an inadequate erythropoietic response to the patient's anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Corrected reticulocyte count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reticulocyte may spend up to 2.5 days in the peripheral blood in severely anemic patients, more than doubling the reticulocyte count without any increase in RBC production (",
"    <a class=\"graphic graphic_figure graphicRef61552 \" href=\"UTD.htm?32/34/33325\">",
"     figure 1",
"    </a>",
"    ). Thus, the absolute reticulocyte count should be corrected for the change in reticulocyte maturation time, particularly if large polychromatophilic RBCs (\"shift cells\") indicative of EPO action are identified on the smear (",
"    <a class=\"graphic graphic_picture graphicRef51682 \" href=\"UTD.htm?8/34/8742\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The corrected absolute reticulocyte count is equal to the absolute reticulocyte count divided by the reticulocyte maturation time (in days). In the above example, the corrected absolute reticulocyte count (60,000 &divide; 2.5) is",
"    <span class=\"nowrap\">",
"     24,000/microL,",
"    </span>",
"    a value markedly lower than normal, indicating a sub-optimal marrow response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Reticulocyte production index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another useful measure of the reticulocyte response is the reticulocyte production index (RPI), which makes two corrections, one for the degree of anemia (normalized to a HCT of 45 percent) and another for the reticulocyte maturation time (RMT), which varies from 1.0 days for a hematocrit of 45 percent to 2.5 days for a hematocrit of 15 percent (",
"    <a class=\"graphic graphic_figure graphicRef61552 \" href=\"UTD.htm?32/34/33325\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    &nbsp;RPI &nbsp;= &nbsp;Reticulocytes (percent) &nbsp;x &nbsp;(HCT &nbsp;&divide; &nbsp;45) &nbsp;x &nbsp;(1 &nbsp;&divide; &nbsp;RMT)",
"   </p>",
"   <p>",
"    The normal RPI is approximately 1.0. It is considered increased, thereby representing an adequate marrow response, if values in excess of 2.0 are obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/4\">",
"     4",
"    </a>",
"    ]. The value for the RPI in the above example is 0.48, an obviously inadequate response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CAUSES OF HEMOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of hemolysis are subdivided into two groups: those that are intrinsic (intracorpuscular) and those extrinsic to the RBC (",
"    <a class=\"graphic graphic_table graphicRef72394 \" href=\"UTD.htm?20/27/20924\">",
"     table 2",
"    </a>",
"    ). With few exceptions (eg, paroxysmal nocturnal hemoglobinuria and the rare condition of",
"    <strong>",
"     acquired",
"    </strong>",
"    alpha thalassemia), the causes of intrinsic RBC defects are hereditary. Extracorpuscular causes are almost always acquired conditions leading to increased destruction of otherwise normal RBCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Intracorpuscular defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracorpuscular defects involve one or more of the RBC components [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Recall that the mature RBC has lost its nucleus, mitochondria, and RNA and is left with three major components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoglobin, the major protein of the red cell, in a concentration of approximately 30 picograms of hemoglobin per individual red cell",
"     </li>",
"     <li>",
"      The RBC membrane, the surface area of which must be about 40 percent greater than that of a sphere of identical volume to allow the RBC to undergo elliptical deformation in the microvasculature. Membrane proteins need to allow for such deformation and elastic recoil. In addition, ion pumps and channels regulate RBC volume via the entry and content of water and the cations sodium, potassium, calcium, and magnesium.",
"     </li>",
"     <li>",
"      Metabolic machinery to generate ATP needed by the cation pumps, 2,3-BPG that allows hemoglobin to take up and release oxygen, and reducing power (eg, glutathione, NADPH) to protect the oxygen-rich RBC from oxidant injury [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of abnormalities in these three systems that lead to hemolysis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoglobin molecules unstable to oxidant challenge, leading to the formation of Heinz bodies, as in hemoglobin K&ouml;ln. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=see_link\">",
"       \"Unstable hemoglobin variants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Membrane injury due to the defective production of either alpha or beta globin chains in thalassemia, leading to the accumulation of excess beta or alpha globin chains, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link\">",
"       \"Pathophysiology of alpha thalassemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"       \"Pathophysiology of beta thalassemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unstable or missing RBC membrane proteins, as in hereditary (congenital) spherocytosis and paroxysmal nocturnal hemoglobinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link\">",
"       \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=see_link\">",
"       \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormalities of RBC hydration, as in xerocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14583?source=see_link\">",
"       \"Xerocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Defective glycolysis, as in pyruvate kinase deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27559?source=see_link\">",
"       \"Pyruvate kinase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormalities in availability of reducing power (NADPH), rendering the RBC susceptible to oxidant challenge, as in glucose-6-phosphate dehydrogenase (G6PD) deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"       \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Extracorpuscular factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major extracorpuscular causes of hemolysis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies directed against RBC membrane components (eg, autoimmune hemolytic anemia, alloimmune hemolytic anemia, delayed [hemolytic] transfusion reaction, some drug-induced hemolytic anemias). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=see_link\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"       \"Immunologic blood transfusion reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stasis, trapping, and destruction of RBC in an enlarged spleen (hypersplenism); the spleen is also the major site of removal of warm antibody-coated red cells and most of the intracorpuscular defects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trauma secondary to high velocity jets (malfunctioning prosthetic aortic valves) or fibrin stands across vessels that shear RBCs in disseminated intravascular coagulation and thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"       \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exposure to compounds with oxidant potential (eg, aniline dyes,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      , pyridium) in normal patients or in those with G6PD deficiency, congenital methemoglobinemia, or unstable hemoglobin variants (eg, sulfonamides). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"       \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=see_link\">",
"       \"Unstable hemoglobin variants\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=see_link\">",
"       \"Genetics and pathogenesis of methemoglobinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Destruction of RBC by pathogens (eg, malaria, babesiosis, clostridium perfringens). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Less common causes include snake and insect bites, certain toxins, thermal burns, copper (eg, Wilson&rsquo;s disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"       \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SITES OF RBC DESTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity and type of red cell alteration determine the cell's site of destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In most cases (eg, oxidant attack, metabolic insult, hemoglobinopathy) this leads to an alteration of the RBC membrane. If the damage is severe enough, immediate lysis occurs within the circulation (ie, intravascular hemolysis). If the damage is less severe, the cell is destroyed within the monocyte-macrophage system in the spleen, liver, bone marrow, and lymph nodes (ie, extravascular hemolysis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intravascular hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Destruction of RBC within the intravascular space requires a considerable amount of structural damage to the RBC membrane. The following are examples (",
"    <a class=\"graphic graphic_table graphicRef72394 \" href=\"UTD.htm?20/27/20924\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct trauma, as in bongo drummers and march hemoglobinuria (also called runners' hemolysis or foot-strike hemolysis)",
"     </li>",
"     <li>",
"      Shear stress, as in defective mechanical heart valves",
"     </li>",
"     <li>",
"      Heat damage, as in thermal burns",
"     </li>",
"     <li>",
"      Complement-induced lysis, as in paroxysmal cold hemoglobinuria",
"     </li>",
"     <li>",
"      Osmotic lysis following infusion of hypotonic solutions",
"     </li>",
"     <li>",
"      Lysis from bacterial toxins (eg, clostridial sepsis)",
"     </li>",
"     <li>",
"      Lysis from exposure to high concentrations of copper",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravascular hemolysis may uncommonly occur following intravenous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/58/11175?source=see_link\">",
"     Rho(D) immune globulin",
"    </a>",
"    to Rho(D)-positive individuals as treatment for immune thrombocytopenia (ITP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Incompletely hemolyzed RBCs, which have lost some of their membrane, can reform and become spherocytes or microspherocytes, while others are destroyed outright. Red cell \"ghosts\", which are red cell membranes devoid of hemoglobin, may be seen under extreme circumstances (",
"    <a class=\"graphic graphic_picture graphicRef53404 \" href=\"UTD.htm?33/25/34193\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When intravascular destruction of red cells occurs, the released hemoglobin appears in the plasma, either as red-colored oxyhemoglobin or the brownish-colored oxidized form, methemoglobin. Free hemoglobin binds to haptoglobin; the resulting hemoglobin-haptoglobin complex is rapidly removed by the liver, leading to a reduction in plasma haptoglobin, often to undetectable levels (see below).",
"   </p>",
"   <p>",
"    The lysed hemoglobin breaks down into alpha-beta dimers, which, if unbound to haptoglobin, are small enough (molecular weight 34,000) to be filtered by the glomerulus and appear in the urine as hemoglobinuria. Although this does not require a high plasma concentration of the free dimer, the total hemoglobin concentration (protein-bound + tetramer + dimer) generally exceeds 100 to 150",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    resulting in a red to brown color of the plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/12\">",
"     12",
"    </a>",
"    ]. Accordingly, red to brown urine in a patient with a normal plasma color is due to a cause other than intravascular hemolysis (eg, myoglobinuria, beet ingestion). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoglobin dimers filtered by the kidney are taken up by renal tubular cells, degraded, and the iron stored as hemosiderin. One week later, when these renal tubular cells are sloughed into the urine, iron can be detected by the Prussian blue reaction performed on the urinary sediment (hemosiderinuria).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Extravascular hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely damaged RBCs, especially those coated with complement, are primarily destroyed in the liver, an organ that receives a larger proportion of the cardiac output than the spleen. The spleen represents more of a challenge to poorly deformable RBCs (eg, spherocytes) due to the cords of Billroth. These unique vascular channels end blindly, unlike other vascular channels in the body. The only way for a RBC, with a diameter of 7 to 8 microns, to escape from these cords and return to the general circulation is to deform sufficiently to pass through 2 to 3 micron slits in the walls of the cords (",
"    <a class=\"graphic graphic_picture graphicRef53105 \" href=\"UTD.htm?25/59/26544\">",
"     picture 3",
"    </a>",
"    ). Senescent or damaged RBCs remain in the cords and are phagocytosed by the macrophage-monocyte system.",
"   </p>",
"   <p>",
"    RBCs destroyed in the spleen are usually phagocytosed in their entirety and digested within phagosomes of macrophages. Most of the hemoglobin is degraded, with each molecule of heme converted to equimolar amounts of biliverdin, iron, and carbon monoxide, via the action of microsomal heme oxygenase.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The biliverdin is immediately reduced to unconjugated bilirubin by the enzyme biliverdin reductase, and is quantitatively released into the plasma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link\">",
"       \"Bilirubin metabolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Under normal circumstances, the iron is efficiently released from macrophages into the plasma, mediated by the iron export protein ferroportin. In patients with the anemia of chronic",
"      <span class=\"nowrap\">",
"       disease/",
"      </span>",
"      inflammation, iron release is impaired, due to the action of hepcidin, which binds to ferroportin and causes its internalization and destruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H5#H5\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Hepcidin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H13#H13\">",
"       \"Regulation of iron balance\", section on 'Ferroportin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"       \"Regulation of iron balance\", section on 'Hepcidin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The carbon monoxide formed from heme breakdown is initially bound to the hemoglobin of intact RBCs as carboxyhemoglobin, released in the pulmonary capillaries, and quantitatively excreted into the expired air.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the highly efficient processes involved, it is possible to gain quantitative information concerning erythropoiesis by following the kinetics of hemoglobin heme, bilirubin, iron,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carbon monoxide [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic approach, starting with an accurate history and physical examination is the cornerstone of the patient's evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H27#H27\">",
"     \"Approach to the adult patient with anemia\", section on 'Evaluation of the patient'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there are no symptoms specific for the diagnosis of hemolytic anemia, recognizing hemolysis is not difficult in the classic patient, who may have many of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid onset of pallor and anemia",
"     </li>",
"     <li>",
"      Jaundice with increased indirect bilirubin concentration",
"     </li>",
"     <li>",
"      History of pigmented (bilirubin) gallstones",
"     </li>",
"     <li>",
"      Splenomegaly",
"     </li>",
"     <li>",
"      Presence of circulating spherocytic red cells (eg, autoimmune hemolytic anemia, congenital spherocytosis)",
"     </li>",
"     <li>",
"      Other informative red cell shape changes (see below)",
"     </li>",
"     <li>",
"      Increased serum lactate dehydrogenase (LDH) concentration",
"     </li>",
"     <li>",
"      Reduced or absent level of serum haptoglobin",
"     </li>",
"     <li>",
"      A positive direct antiglobulin test (Coombs test)",
"     </li>",
"     <li>",
"      Increased reticulocyte percentage or absolute reticulocyte number, indicating the bone marrow's response to the anemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory findings, including an examination of the peripheral smear, are used to confirm the presence of hemolysis, and, if possible, the underlying cause (",
"    <a class=\"graphic graphic_table graphicRef72394 \" href=\"UTD.htm?20/27/20924\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hematologic consultation should be obtained in virtually all patients with a new onset of hemolysis, since sudden and life-threatening worsening of anemia may occur, requiring urgent coordination between clinicians, clinical pathologists, and blood bank personnel for appropriate management. Hemolysis may also be the first sign of an underlying systemic disorder (eg, thrombotic thrombocytopenic purpura, lupus erythematosus, chronic lymphocytic leukemia) and may require urgent intervention to prevent death or disease-related complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Peripheral smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory provision of RBC indices and description of the smear cannot be substituted for the individual physician's ability to detect abnormal RBC forms on the peripheral smear in a patient presenting with anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormalities suspicious for the presence of hemolysis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spherocytes (",
"      <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"       picture 4",
"      </a>",
"      ), microspherocytes, and elliptocytes (",
"      <a class=\"graphic graphic_picture graphicRef63129 \" href=\"UTD.htm?9/61/10199\">",
"       picture 5",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link\">",
"       \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Fragmented RBC (schistocytes, helmet cells) indicating the presence of microangiopathic hemolytic anemia (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acanthocytes (spur cells) in patients with liver disease (",
"      <a class=\"graphic graphic_picture graphicRef80080 \" href=\"UTD.htm?14/26/14760\">",
"       picture 7",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link&amp;anchor=H14#H14\">",
"       \"Extrinsic nonimmune hemolytic anemia due to systemic disease\", section on 'Liver disease'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Blister or \"bite\" cells due to the presence of oxidant-induced damage to the red cell and its membrane (",
"      <a class=\"graphic graphic_picture graphicRef73790 \" href=\"UTD.htm?25/28/26054\">",
"       picture 8",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"       \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      RBCs with inclusions, as in malaria, babesiosis, and Bartonella infections (",
"      <a class=\"graphic graphic_picture graphicRef77517 \" href=\"UTD.htm?6/11/6327\">",
"       picture 9",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link&amp;anchor=H5#H5\">",
"       \"Extrinsic nonimmune hemolytic anemia due to systemic disease\", section on 'Infection'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Teardrop RBCs with circulating nucleated RBC and early white blood cell forms, indicating the presence of marrow involvement, as in primary myelofibrosis or tumor infiltration (",
"      <a class=\"graphic graphic_picture graphicRef55274 graphicRef68110 \" href=\"UTD.htm?18/43/19130\">",
"       picture 10A-B",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Red cell \"ghosts\" (",
"      <a class=\"graphic graphic_picture graphicRef53404 \" href=\"UTD.htm?33/25/34193\">",
"       picture 2",
"      </a>",
"      ), indicating the presence of intravascular hemolysis, most often associated with overwhelming bacterial infection (eg, clostridium perfringens). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link&amp;anchor=H12#H12\">",
"       \"Extrinsic nonimmune hemolytic anemia due to systemic disease\", section on 'Clostridium perfringens'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Serum LDH and haptoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major tests used to diagnose the presence of hemolysis are lactate dehydrogenase (LDH, specifically the LD1 and LD2 isoenzymes which are found primarily in RBCs and heart muscle), released from hemolyzed RBCs, and haptoglobin, which binds to hemoglobin released during intravascular or extravascular hemolysis or ineffective erythropoiesis with release of hemoglobin from late erythroid precursors in the bone marrow. There are some caveats in assessing these tests, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An elevated LDH level is also a marker of nonspecific tissue damage and is one of the factors correlating with reduced survival in patients with non-Hodgkin lymphoma. The clinical picture and the level of the various LDH isoenzymes may provide clues to its source [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=see_link&amp;anchor=H17219017#H17219017\">",
"       \"Prognosis of diffuse large B cell lymphoma\", section on 'International Prognostic Index'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28101?source=see_link&amp;anchor=H8#H8\">",
"       \"Biomarkers of cardiac injury other than troponins and creatine kinase\", section on 'Lactate dehydrogenase'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Higher haptoglobin values in the presence of hemolysis can reflect either a lesser degree of hemolysis or concurrent inflammation, since haptoglobin is an acute phase reactant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"       \"Acute phase reactants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The normal range for serum haptoglobin is wide, with the lower limits of normal in the range of 17 to 35",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in some laboratories. Thus, while low levels of haptoglobin are often seen, undetectable levels (eg, &lt;7",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      are almost always associated with clinical hemolysis, with the exception of rare individuals with congenital anhaptoglobinemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one series of reports, the combination of an increased serum LDH and a reduced haptoglobin was 90 percent specific for diagnosing hemolysis, while the combination of a normal serum LDH and a serum haptoglobin &gt;25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    was 92 percent sensitive for ruling out hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Reticulocyte count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal reticulocyte percentage is 0.5 to 1.5 percent (",
"    <a class=\"graphic graphic_table graphicRef64238 \" href=\"UTD.htm?41/52/42827\">",
"     table 1",
"    </a>",
"    ). In patients with an otherwise intact bone marrow, the increase in erythropoietin production induced in a patient with hemolytic anemia should raise the reticulocyte percentage above 4 to 5 percent. In one series of patients with autoimmune hemolytic anemia, for example, the median reticulocyte percentage at diagnosis was 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with lesser degrees of hemolysis may not become anemic (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Hemolysis without anemia'",
"    </a>",
"    below). However, when the bone marrow is compromised (eg, following chemotherapy, infection, underlying marrow disease, cobalamin, folate, or iron deficiency), the reticulocyte response may be blunted or ablated (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Hemolysis without reticulocytosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In general, more information concerning the reticulocyte response can be gained from a determination of the absolute reticulocyte count",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the reticulocyte production index (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Reticulocyte response'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests helpful in determining the presence or absence of hemolysis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased serum concentrations of indirect bilirubin from the catabolism of hemoglobin heme. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"       \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased mean corpuscular hemoglobin concentration (MCHC), indicating the presence of spherocytes (",
"      <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Positive direct antiglobulin (Coombs') test in autoimmune hemolytic anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Antibody detection: the direct Coombs' test'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tests for cold agglutinins or the Donath-Landsteiner antibody if symptoms are related to exposure to cold. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=see_link\">",
"       \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=see_link\">",
"       \"Paroxysmal cold hemoglobinuria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testing for the presence of insoluble globin particles within the red blood cell (ie, Heinz bodies). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=see_link&amp;anchor=H14#H14\">",
"       \"Unstable hemoglobin variants\", section on 'Heinz body formation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased blood concentration of carboxyhemoglobin due to hemoglobin heme catabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/20\">",
"       20",
"      </a>",
"      ]. This test is not generally available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Testing for intravascular hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If intravascular hemolysis is suspected, the following additional tests are of value (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Intravascular hemolysis'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of the PLASMA hemoglobin concentration (ie, testing for hemoglobinemia)",
"     </li>",
"     <li>",
"      Measurement of free hemoglobin in the urine supernatant (ie, testing for hemoglobinuria)",
"     </li>",
"     <li>",
"      Testing for hemosiderin in the urine sediment &ge;7 days after the incident, allowing time for hemosiderin-containing tubular cells to be shed into the urine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Serial evaluation of Hgb and HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measuring the rate of fall of the Hgb or HCT often provides helpful diagnostic information. Suppose the HCT concentration has fallen from 45 to 30 percent in one week. If this were due to total cessation of RBC production (ie, a reticulocyte count of zero) and if the rate of RBC destruction were normal (1",
"    <span class=\"nowrap\">",
"     percent/day),",
"    </span>",
"    the HCT would have fallen to 93 percent of its initial value over the next seven days, resulting in a decline in the HCT to 42 percent (0.93 x 45). A fall greater than this, in the absence of significant changes in plasma volume (eg, intravenous hydration), strongly suggests the presence of hemolysis or blood loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ATYPICAL PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is useful to remember that anemia may be multi-factorial. Thus, in any patient with hemolytic anemia, the presence of blood loss may aggravate the degree of anemia. Similarly, the degree to which the patient's bone marrow can respond to anemia will determine whether the patient will have hemolysis without anemia or hemolysis without an appropriate reticulocyte response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hemolysis without anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolysis may exist without anemia if the rate of RBC destruction falls within the marrow's compensatory ability (5 and 8 times normal in adults and children, respectively). Thus, as in 20 to 30 percent of hereditary spherocytosis kindreds, Hgb and HCT will be normal if the rate of RBC destruction is less than this. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the lack of anemia, hemolysis can still be detected from elevations in the reticulocyte percentage, absolute reticulocyte count, serum indirect bilirubin, and LDH concentrations, and reduction in serum haptoglobin. An estimate of RBC turnover from the reticulocyte count in non-anemic patients (see",
"    <a class=\"local\" href=\"#H2\">",
"     'RBC kinetics'",
"    </a>",
"    above) should yield a value of &le;5 or &le;8 percent per day in adults and children, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hemolysis without reticulocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemia can be seen in the absence of red cell renewal, in the form of a reduced or absent reticulocyte response and a more profound degree of anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/21\">",
"     21",
"    </a>",
"    ]. As an example, in a study of 109 patients with autoimmune hemolytic anemia, 20 percent had an initial reticulocyte percentage &lt;4 percent and 37 percent had an initial reticulocyte production index (RPI) &lt;2.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/4\">",
"     4",
"    </a>",
"    ]. Three-fourths of these patients had erythroid hyperplasia on bone marrow examination; repeat studies ultimately revealed an appropriately elevated RPI in 85 percent.",
"   </p>",
"   <p>",
"    In most cases, the poor reticulocyte response at presentation may represent a transient lag in marrow responsiveness to the hemolytic stress. In other cases of autoimmune hemolytic anemia, the antibody may also destroy red cell precursors, preventing a reticulocyte response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemolysis may also be associated with a more persistent absence of an appropriate reticulocyte response:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Direct marrow suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The marrow will not respond appropriately if it is damaged or suppressed. This can occur in patients with hereditary hemolytic anemias (eg, sickle cell anemia, hereditary spherocytosis) during an aplastic crisis caused by infection with the parvovirus B19 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. In one study, 91 of 114 B19-infected patients with sickle cell disease developed transient aplastic crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/3\">",
"     3",
"    </a>",
"    ]. Such patients have a temporary but profound worsening of their anemia, with a reduced or absent reticulocyte response, due to a direct viral damage to RBC precursors.",
"   </p>",
"   <p>",
"    It is unclear if the incidence of this infection is increased in patients with hereditary hemolytic anemias or if the discovery rate is higher because RBC aplasia in the presence of hemolysis leads to a much more rapid and clinically evident anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bone marrow may also be suppressed as a consequence of chemotherapy. An example is the patient with autoimmune hemolytic anemia secondary to chronic lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18489/abstract/23\">",
"     23",
"    </a>",
"    ], who is being treated with marrow-suppressing doses of chemotherapeutic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Indirect marrow suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of plasma iron is rate-limiting for RBC production. Thus, any disorder that causes a reduced plasma iron impairs the patient's erythropoietic response. Examples include iron deficiency and the anemia of chronic",
"    <span class=\"nowrap\">",
"     disease/",
"    </span>",
"    inflammation. A similar effect can be induced by erythropoietin deficiency in patients with advanced renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Suspecting hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspecting the diagnosis of hemolysis is not difficult in the classic patient, who may have many of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid onset of pallor and anemia",
"     </li>",
"     <li>",
"      Jaundice with increased indirect bilirubin concentration",
"     </li>",
"     <li>",
"      History of pigmented (bilirubin) gallstones",
"     </li>",
"     <li>",
"      Splenomegaly",
"     </li>",
"     <li>",
"      Presence of circulating spherocytic red cells or red cells with other shape changes",
"     </li>",
"     <li>",
"      Increased serum lactate dehydrogenase (LDH) concentration",
"     </li>",
"     <li>",
"      Reduced (or absent) level of serum haptoglobin",
"     </li>",
"     <li>",
"      A positive direct antiglobulin test (Coombs test)",
"     </li>",
"     <li>",
"      Increased reticulocyte percentage or absolute reticulocyte number, indicating the bone marrow's response to the anemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Confirming hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of an increased serum LDH and a reduced haptoglobin is 90 percent specific for diagnosing hemolysis, while the combination of a normal serum LDH and a serum haptoglobin &gt;25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is 92 percent sensitive for ruling out the presence of hemolysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities on the peripheral blood smear suggesting extravascular hemolysis include: spherocytes, microspherocytes, elliptocytes, \"bite\" or blister cells, acanthocytes, and teardrop red cells.",
"     </li>",
"     <li>",
"      Abnormalities that suggest that the hemolysis is intravascular include the presence of free hemoglobin in plasma or urine, a urine sediment positive for iron (hemosiderinuria), and, in rare cases, the presence of circulating red cell \"ghosts.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Determining the cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different causes for hemolysis are reviewed above (",
"    <a class=\"graphic graphic_table graphicRef72394 \" href=\"UTD.htm?20/27/20924\">",
"     table 2",
"    </a>",
"    ). A thorough history and physical examination is important, as many of these causes include drugs and toxins or systemic disorders (eg, infection, autoimmune disease, malignancy). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Causes of hemolysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no \"generic\" treatment for hemolytic anemia. Appropriate management of a patient with hemolytic anemia requires that the underlying cause be determined. Treatment of the different causes of hemolytic anemia is discussed elsewhere in UpToDate, under the specific underlying disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/1\">",
"      Poyart C, Wajcman H. Hemolytic anemias due to hemoglobinopathies. Mol Aspects Med 1996; 17:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/2\">",
"      OWREN PA. Congenital hemolytic jaundice; the pathogenesis of the hemolytic crisis. Blood 1948; 3:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/3\">",
"      Serjeant GR, Serjeant BE, Thomas PW, et al. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993; 341:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/4\">",
"      Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood 1987; 69:820.",
"     </a>",
"    </li>",
"    <li>",
"     Erslev AJ. Reticulocyte enumeration. In: Williams' Hematology, 5th ed, Beutler E, Lichtman MA, Coller BS, et al. (Eds), McGraw-Hill, New York 1995. p.L28.",
"    </li>",
"    <li>",
"     Red blood cell diseases: Red cell production, red cell indices, and the reticulocyte count. In: Hematology. A Pathophysiological Approach, Babior BM, Stossel TP (Eds), Churchill Livingstone, New York 1984. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/7\">",
"      Jacobasch G, Rapoport SM. Hemolytic anemias due to erythrocyte enzyme deficiencies. Mol Aspects Med 1996; 17:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/8\">",
"      Bossi D, Russo M. Hemolytic anemias due to disorders of red cell membrane skeleton. Mol Aspects Med 1996; 17:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/9\">",
"      van Wijk R, van Solinge WW. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood 2005; 106:4034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/10\">",
"      Cazzola M, Beguin Y. New tools for clinical evaluation of erythron function in man. Br J Haematol 1992; 80:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/11\">",
"      Bossi D, Giardina B. Red cell physiology. Mol Aspects Med 1996; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/12\">",
"      Pimstone NR. Renal degradation of hemoglobin. Semin Hematol 1972; 9:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/13\">",
"      Pollycove M. Iron metabolism and kinetics. Semin Hematol 1966; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/14\">",
"      Berlin NI, Berk PD. Quantitative aspects of bilirubin metabolism for hematologists. Blood 1981; 57:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/15\">",
"      Coburn RF, Williams WJ, White P, Kahn SB. The production of carbon monoxide from hemoglobin in vivo. J Clin Invest 1967; 46:346.",
"     </a>",
"    </li>",
"    <li>",
"     Landaw SA. Homeostasis, survival and red cell kinetics: Measurement and imaging of red cell production. In: Hematology. Basic Principles and Practice, 2nd ed, Hoffman R, Benz EJ, Shattil SJ (Eds), Churchill Livingstone, New York 1995. p.448.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/17\">",
"      Ballas SK. Lactate dehydrogenase and hemolysis in sickle cell disease. Blood 2013; 121:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/18\">",
"      Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980; 243:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/19\">",
"      Galen RS. Application of the predictive value model in the analysis of test effectiveness. Clin Lab Med 1982; 2:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/20\">",
"      Hammerman C, Vreman HJ, Kaplan M, Stevenson DK. Intravenous immune globulin in neonatal immune hemolytic disease: does it reduce hemolysis? Acta Paediatr 1996; 85:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/21\">",
"      Conley CL, Lippman SM, Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA 1980; 244:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/22\">",
"      Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18489/abstract/23\">",
"      Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25:80.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7076 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18489=[""].join("\n");
var outline_f18_3_18489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RBC KINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Random hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RBC lifespan and turnover",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical example: transient aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RETICULOCYTE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Absolute reticulocyte count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Corrected reticulocyte count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Reticulocyte production index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CAUSES OF HEMOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Intracorpuscular defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Extracorpuscular factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SITES OF RBC DESTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intravascular hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Extravascular hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Serum LDH and haptoglobin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Reticulocyte count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Testing for intravascular hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Serial evaluation of Hgb and HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ATYPICAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hemolysis without anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hemolysis without reticulocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Direct marrow suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Indirect marrow suppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Suspecting hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Confirming hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Determining the cause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7076|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/34/33325\" title=\"figure 1\">",
"      Reticulocyte shift",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7076|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/34/8742\" title=\"picture 1\">",
"      Shift cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/25/34193\" title=\"picture 2\">",
"      Intravascular hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/59/26544\" title=\"picture 3\">",
"      Red cells in the spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/1/27670\" title=\"picture 4\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/61/10199\" title=\"picture 5\">",
"      Elliptocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 6\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/26/14760\" title=\"picture 7\">",
"      Acanthocytes or spur cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/28/26054\" title=\"picture 8\">",
"      Heinz body hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/11/6327\" title=\"picture 9\">",
"      Malaria trophozoites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/37/43606\" title=\"picture 10A\">",
"      Tear drop cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/43/30390\" title=\"picture 10B\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7076|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/52/42827\" title=\"table 1\">",
"      Normal red cell values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/27/20924\" title=\"table 2\">",
"      Causes intra- and extra-vascular hemolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28101?source=related_link\">",
"      Biomarkers of cardiac injury other than troponins and creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=related_link\">",
"      Genetics and pathogenesis of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=related_link\">",
"      Paroxysmal cold hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27559?source=related_link\">",
"      Pyruvate kinase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=related_link\">",
"      Unstable hemoglobin variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14583?source=related_link\">",
"      Xerocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_3_18490="Management of migraine headache in children";
var content_f18_3_18490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of migraine headache in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/3/18490/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/3/18490/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/3/18490/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/3/18490/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/3/18490/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/3/18490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/3/18490/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/3/18490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is the most common acute and recurrent headache syndrome in children. It is characterized by periodic episodes of paroxysmal headache accompanied by nausea, vomiting, abdominal pain, and relief with sleep.",
"   </p>",
"   <p>",
"    The management of migraine consists of general measures, abortive treatment, and prophylactic treatment. An individual patient may need all three approaches. Unfortunately, there is a paucity of data from controlled, randomized and blinded trials regarding treatment of migraine in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Thus, most management recommendations are based upon experience in adults.",
"   </p>",
"   <p>",
"    The management of migraine is reviewed here. The epidemiology, pathophysiology, clinical features, and diagnosis of migraine headaches are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8600?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of migraine in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education of the family is important in management. Literature describing migraine in children should be provided. The family should be asked to document the occurrence of headaches on a calendar to clarify features of the attacks and to help evaluate the effectiveness of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If possible, precipitating factors should be identified. As an example, the use of caffeine may exacerbate migraine and should be eliminated. Sleep disturbances, such as snoring or frequent awakenings, may precipitate headache. Rarely, a temporal relationship is established between diet and headache; in these cases, an elimination diet may be helpful. Dehydration and missing meals are also common precipitants of migraine. Stress caused by school or social situations may increase headache frequency, although stress does not cause migraine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ABORTIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early use of medication is an important principle of acute treatment. This may be difficult in young children, who often do not report a migraine until symptoms are severe. The younger the child, the more difficult it is to treat migraine effectively with intermittent medication.",
"   </p>",
"   <p>",
"    Migraine headaches usually are treated at home. The treatment plan should be straightforward and safe. The parents typically decide when treatment is indicated and when to administer medication. In general, young children are not able to medicate themselves. In the school-age child, arrangements must be made for a school professional to administer medicine.",
"   </p>",
"   <p>",
"    When symptoms develop, the child should rest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sleep in a quiet dark room with a cool cloth applied to the forehead. The initial treatment consists of an analgesic and may include an antiemetic.",
"   </p>",
"   <p>",
"    Improper chronic daily use of abortive headache medications should be avoided. Although they are thought to be benign, they may lead to a type of chronic daily headache known as medication overuse headache (previously termed analgesic rebound headache). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=see_link&amp;anchor=H661158092#H661158092\">",
"     \"Approach to the child with headache\", section on 'Chronic daily headache'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the literature and clinical experience, the risk for medication overuse headache appears to be highest with opioids, butalbital-containing combination analgesics, and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"      aspirin",
"     </a>",
"     /",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"      acetaminophen",
"     </a>",
"     /caffeine",
"    </span>",
"    combinations. The risk with triptans is considered intermediate by some experts but high by others. The risk is lowest with nonsteroidal antiinflammatory drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=see_link&amp;anchor=H8#H8\">",
"     \"Medication overuse headache: Etiology, clinical features, and diagnosis\", section on 'Causal medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of medication overuse headache should be suspected in patients who have frequent headaches despite the regular use of analgesic medications. The treatment involves patient education, withdrawal of the offending medication, bridge (transitional) therapy aimed at symptomatic relief during medication withdrawal, establishment of an appropriate headache treatment regimen covering acute and preventive care, and relapse prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=see_link\">",
"     \"Medication overuse headache: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Triptans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The triptans represent a significant advance in the abortive treatment of migraine. They are serotonin agonists with an affinity for the 5-HT",
"    <span class=\"nowrap\">",
"     1b/1d",
"    </span>",
"    receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/5\">",
"     5",
"    </a>",
"    ]. Triptans are thought to have multiple mechanisms of action. All of the triptans inhibit the release of vasoactive peptides, promote vasoconstriction, and block pain pathways in the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Triptans inhibit transmission in the trigeminal nucleus caudalis, thereby blocking afferent input to second order neurons; this effect is probably mediated by reducing the levels of calcitonin gene related peptide (CGRP) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8600?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology, clinical features, and diagnosis of migraine in children\", section on 'Role of CGRP'",
"    </a>",
"    ). Triptans may also activate 5-HT",
"    <span class=\"nowrap\">",
"     1b/1d",
"    </span>",
"    receptors in descending brainstem pain modulating pathways and thereby inhibit dural nociception [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The triptans are widely used in children, although such use is mostly off-label [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/8\">",
"     8",
"    </a>",
"    ]. Nasal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    and nasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"     zolmitriptan",
"    </a>",
"    have the strongest efficacy data in pediatric populations. However, we usually begin treatment with oral triptans because they are easier to use and are more acceptable to children, who generally have an aversion to nasal or subcutaneous administration.",
"   </p>",
"   <p>",
"    Triptans should be used with caution in basilar artery and hemiplegic migraine because of theoretical concerns about aggravating symptoms that may be caused by vasospasm.",
"   </p>",
"   <p>",
"    Concerns have also been raised about the development of a serotonin syndrome in patients who use triptans in combination with a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin-norepinephrine reuptake inhibitor (SNRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the risk of serotonin syndrome posed by the combined use of a triptan with an SSRI or SNRI appears to be very low to nonexistent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Thus, many headache experts suggest that triptans in combination with SSRIs or SNRIs can be used in most cases where both are needed as long as the risks and benefits are discussed, and patients are monitored for symptoms of serotonin syndrome. The combination should be discontinued if such symptoms arise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27076669\">",
"    <span class=\"h3\">",
"     Oral triptans",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large placebo-controlled randomized trial showed that oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32388?source=see_link\">",
"     almotriptan",
"    </a>",
"    was beneficial for relieving migraine in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/12\">",
"     12",
"    </a>",
"    ]. Some but not all studies have found benefit with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/24/8581?source=see_link\">",
"     rizatriptan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"     zolmitriptan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/8,13-16\">",
"     8,13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data for oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    in adolescent children include one small published trial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/17\">",
"     17",
"    </a>",
"    ] and three trials available only in abstract form [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/8\">",
"     8",
"    </a>",
"    ]. These trials found no benefit for oral sumatriptan compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in our clinical experience, oral sumatriptan is effective and useful in adolescent children.",
"   </p>",
"   <p>",
"    The initial dose of oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    in adolescents is 25 mg given as soon as possible after the onset of migraine headache. The dose should be adjusted on an individual basis to a maximum single dose of 50 mg for younger adolescents and 100 mg for older adolescents. The dose may be repeated after two hours, with a maximum of 200",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Nasal sumatriptan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines published in 2004 concluded that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    nasal spray is effective and should be considered for the acute treatment of migraine in adolescents 12 to 17 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/1\">",
"     1",
"    </a>",
"    ]. Another systematic review that included three randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/18-20\">",
"     18-20",
"    </a>",
"    ] concluded that sumatriptan nasal spray was more effective than placebo in reducing migraine headache (pooled RR 1.4, 95% CI 1.2-1.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest of the included trials, 653 adolescents (12 to 17 years old) with migraine were assigned randomly to one of three doses (5, 10, 20 mg) of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/19\">",
"     19",
"    </a>",
"    ]. Headache relief two hours after the 20 mg dose of sumatriptan, the primary endpoint, occurred more often than with placebo (63 versus 53 percent), approaching significance. Complete relief two hours after the dose was significantly greater with sumatriptan (36 versus 25 percent).",
"   </p>",
"   <p>",
"    Efficacy of the doses appeared to vary with age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients 12 to 14 years old responded better to the lower doses, whereas the 20 mg dose was more effective in patients 15 to 17 years old. Treatment also significantly reduced photophobia and phonophobia. Taste disturbance, the most frequently reported adverse event, occurred in 26, 30, 19, and 2 percent of patients treated with 20, 10, and 5 mg",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    , and placebo, respectively. No serious adverse events occurred.",
"   </p>",
"   <p>",
"    The incidence of recurrent migraine following",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    therapy is thought to be less in children than in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/22\">",
"     22",
"    </a>",
"    ]. This is possibly because the duration of headache is shorter in children.",
"   </p>",
"   <p>",
"    Nasal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    is given to younger children in an initial dose of 5 mg. If this dose is ineffective, 10 mg can be tried. In adolescents, a dose of up to 20 mg can be given. The bad taste that may accompany use of the nasal spray can by lessened by tilting the head forward during administration and sucking on a flavored lozenge or piece of hard candy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Subcutaneous sumatriptan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small open label studies suggest that subcutaneous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    may be an effective therapy for migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In one of these reports, subcutaneous sumatriptan was evaluated in a series of 17 children, 6 to 16 years old, with severe migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/23\">",
"     23",
"    </a>",
"    ]. After a 6 mg dose, headache was relieved within one or two hours in 6 and 5 of 15 patients, respectively. Two smaller children had complete relief two hours after a 3 mg dose. In another study of 50 children, 6 to 18 years old, headache response was 78 percent overall, with 30, 60, and 60 to 120 minute response rates of 26, 46, and 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nasal zolmitriptan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from a multicenter randomized clinical trial suggest that nasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"     zolmitriptan",
"    </a>",
"    is effective for acute treatment of migraine in adolescent children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/25\">",
"     25",
"    </a>",
"    ]. The trial enrolled 248 children (12 to 17 years old) with migraine (with or without aura) and employed a novel study design because of an anticipated high placebo response rate. Each migraine attack was treated initially with placebo nasal spray (single-blind) when the headache reached moderate or severe intensity. If the migraine intensity remained moderate to severe, patients were then randomly assigned (double-blind) to zolmitriptan 5 mg nasal spray or placebo nasal spray. The following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On the primary outcome measure of headache response at one hour after treatment,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      nasal spray treatment was associated with a higher rate of response than placebo (58 versus 43 percent), and the difference was statistically significant (odds ratio 1.83, 95% CI 1.14-2.94)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       Zolmitriptan",
"      </a>",
"      nasal spray was significantly more effective than placebo on a number of secondary outcome measures, including improvement in pain intensity, pain-free rates, sustained resolution of headache, and resolution of associated migraine symptoms",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       Zolmitriptan",
"      </a>",
"      was well-tolerated, and no patient withdrew from the study because of adverse events. The most common adverse events with zolmitriptan nasal spray were taste disturbance and nasal discomfort in 6.5 and 2.5 percent of patients, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     NSAIDs and acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonsteroidal anti-inflammatory drugs (NSAIDs) often are effective treatment. Early administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is helpful.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     Aspirin",
"    </a>",
"    should be avoided because of concern about Reye syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link&amp;anchor=H28202936#H28202936\">",
"     \"Acute toxic-metabolic encephalopathy in children\", section on 'Reye syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines published in 2004 concluded that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is effective and that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is probably effective for the acute treatment of migraine in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar conclusions were noted in another systematic review; the relative risk of headache reduction for either agent within two hours of administration was 1.5 compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    may provide faster relief, as demonstrated in a double-masked crossover study of 88 children, aged 4 to 15.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/26\">",
"     26",
"    </a>",
"    ]. Three attacks in each child were treated randomly with single oral doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    ibuprofen (10",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    or placebo. Ibuprofen and acetaminophen were three and two times, respectively, more likely to reduce headache severity than was placebo. The headache was aborted within two hours twice as often with ibuprofen than with acetaminophen.",
"   </p>",
"   <p>",
"    For patients with pain that is severe and disabling but occurs infrequently, one of the following drugs can be used at the onset of the headache [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      is administered in an initial dose of 10 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (usually as one or two 325 mg tablets), with a maximum dose of 1000 mg. A second dose of 10 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      may be given in two to four hours if symptoms persist. Additional doses may be given at four- to six-hour intervals, but should not exceed three doses in 24 hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      is given in a dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      This dose may be repeated in four to six hours if needed. No more than four doses should be given in 24 hours (maximum daily dose 40",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      Ibuprofen should be used with caution in patients with chronic abdominal pain, dizziness, or tinnitus.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/61/27608?source=see_link\">",
"       Naproxen",
"      </a>",
"      (250 mg tablet) can be given to children older than 12 years of age. The dose can be repeated up to three times per day at 8- to 12-hour intervals. Naproxen should be used with caution in patients with epigastric pain or worsening nausea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/43/34480?source=see_link\">",
"     Ketorolac",
"    </a>",
"    (intravenous) may also be beneficial for pediatric migraine, but placebo-controlled data are not available. A randomized trial comparing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/14/5351?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    versus ketorolac found that intravenous ketorolac (0.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum 30 mg) successfully treated migraine within 60 minutes in 55 percent of 29 children, with a 50 percent or greater reduction in the pain score [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/28\">",
"     28",
"    </a>",
"    ]. However, intravenous prochlorperazine was more effective. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Antiemetics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In children 2 to 16 years of age,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/43/34480?source=see_link\">",
"     ketorolac",
"    </a>",
"    is approved for use only as a single intramuscular or intravenous dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207323099\">",
"    <span class=\"h2\">",
"     Sumatriptan plus naproxen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/61/27608?source=see_link\">",
"     naproxen",
"    </a>",
"    was superior to placebo for the treatment of acute migraine headache in a randomized controlled trial of 490 adolescents (12 to 17 years old) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/29\">",
"     29",
"    </a>",
"    ]. At two hours, adolescents assigned to three different doses of combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41527?source=see_link\">",
"     sumatriptan-naproxen",
"    </a>",
"    tablets",
"    <span class=\"nowrap\">",
"     (10/60",
"    </span>",
"    mg,",
"    <span class=\"nowrap\">",
"     30/180",
"    </span>",
"    mg, and",
"    <span class=\"nowrap\">",
"     85/500",
"    </span>",
"    mg) had significantly higher pain-free rates (29, 27, and 24 percent, respectively) compared with those assigned to placebo (10 percent). All three doses of combination sumatriptan-naproxen were well tolerated.",
"   </p>",
"   <p>",
"    Given these data, we suggest combination",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     sumatriptan",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/61/27608?source=see_link\">",
"     naproxen",
"    </a>",
"    for children and adolescents with acute migraine headache without vomiting who do not respond to monotherapy with other abortive migraine medications. While doses used in the trial are appropriate for adolescents age 12 years and older whose weight is &ge;74 lbs (&ge;33.3 kg), sumatriptan and naproxen dosing for younger or smaller children should be reduced based upon body weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs sometimes used for headache include opioids, barbiturates, and benzodiazepines. However, these drugs should not be used because they are habit-forming. A preparation once commonly used in adolescents and children older than eight years of age is the combination drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/32/23045?source=see_link\">",
"     acetaminophen-isometheptene-dichloralphenazone",
"    </a>",
"    (Midrin). However, this drug is no longer marketed in the United States and is not widely available in other countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antiemetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early use of an antiemetic may relieve symptoms and facilitate sleep if nausea and vomiting are prominent. Rectal administration may be preferable because of the difficulty of retaining orally administered drugs in a patient with nausea and vomiting.",
"   </p>",
"   <p>",
"    The phenothiazines may have additional antimigraine properties, although few studies are available.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"     Promethazine",
"    </a>",
"    is the phenothiazine most commonly used in children because it is effective and has a low incidence of acute extrapyramidal reactions, such as oculogyric crisis. The dose is 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose orally, intramuscularly, or rectally; it should NOT be administered intravenously. Promethazine should NOT be given to children who are less than two years old because of the potential for severe and potentially fatal respiratory depression.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/14/5351?source=see_link\">",
"     Prochlorperazine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    also are effective, but they are used less commonly in children because of concerns about extrapyramidal reactions, although the frequency of this complication is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/30\">",
"     30",
"    </a>",
"    ]. A single randomized trial of 62 children presenting to the emergency department with migraine headaches compared intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/43/34480?source=see_link\">",
"     ketorolac",
"    </a>",
"    with intravenous prochlorperazine (not placebo); successful treatment of migraine was defined as a 50 percent or greater reduction in pain score within 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/28\">",
"     28",
"    </a>",
"    ]. Prochlorperazine was significantly more effective than ketorolac in achieving treatment success (85 and 55 percent respectively) and in decreasing the mean pain score. In a retrospective study of 20 consecutive children seen in the emergency department for severe prolonged migraine, treatment with prochlorperazine (0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously) reduced pain severity in most patients; after three hours, 60 percent reported no pain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/31\">",
"     31",
"    </a>",
"    ]. No significant side effects were seen.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/15/11509?source=see_link\">",
"     Dimenhydrinate",
"    </a>",
"    also is an effective antiemetic. The dose is 1.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally or intramuscularly every four to six hours.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    administered intravenously appears to reduce nausea and vomiting associated with migraine. Its use in children usually is reserved for the emergency department and for protracted migraine. It commonly is used prior to the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/3/44085?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Dihydroergotamine'",
"    </a>",
"    below). In one trial, adults with migraine seen in an emergency department were assigned randomly to treatment with metoclopramide with or without",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/32\">",
"     32",
"    </a>",
"    ]. Metoclopramide resulted in significantly better relief of pain and nausea than ibuprofen or placebo. The effect of metoclopramide was similar with or without ibuprofen.",
"   </p>",
"   <p>",
"    Acute dystonic reactions may occur with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This complication is thought to occur more commonly in patients younger than 25 years of age. Thus, metoclopramide should be used with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dihydroergotamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravenous (IV) preparation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/3/44085?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    (DHE) often is effective in the treatment of severe migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/35\">",
"     35",
"    </a>",
"    ]. This point is illustrated by findings from a retrospective report that reviewed the inpatient treatment of status migrainosus in 32 children (mean age 15 years) who were treated with IV DHE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/36\">",
"     36",
"    </a>",
"    ]. At time of discharge (mean length of stay three days), approximately 75 percent of the children were headache free. Treatment was well tolerated; nausea was the most frequent side effect.",
"   </p>",
"   <p>",
"    The dose of IV DHE used in this study for children age 10 years and older was 1 mg over three minutes every eight hours, with a maximum of 20 doses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/36\">",
"     36",
"    </a>",
"    ]. For children &lt;25 kg or age nine years and younger, the dose was 0.5 mg every eight hours. Prior to being treated with DHE, all patients received a test dose of DHE (one-half the initial dose appropriate for age and weight) and all girls had to have a negative pregnancy test. In addition, all patients were pretreated with an antiemetic 30 minutes prior to each DHE dose using either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/14/5351?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    for the first three doses, followed by",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    as needed for remaining doses (to prevent the extrapyramidal side effects that can occur with the antidopaminergic drugs).",
"   </p>",
"   <p>",
"    In an earlier study, 80 percent of children with migraine without aura who failed outpatient treatment responded to IV DHE plus oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/37\">",
"     37",
"    </a>",
"    ]. Side effects were minimal.",
"   </p>",
"   <p>",
"    The use of intravenous DHE in children usually is restricted to the treatment of protracted migraine that has not responded to other therapies. It is administered in the emergency department or inpatient setting. Common side effects of DHE include nausea and anxiety; dyskinesia may occur infrequently. Patients should be pretreated with antiemetic medication (eg",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/14/5351?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ) 30 minutes prior to each dose of DHE. With extended use of DHE, antidopaminergic drugs should be avoided and alternate antiemetic agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    ) used instead.",
"   </p>",
"   <p>",
"    Ergot preparations should",
"    <strong>",
"     not",
"    </strong>",
"    be used in basilar artery and hemiplegic migraine since they may aggravate symptoms caused by vasospasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other ergotamine preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of sublingual, oral, and rectal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/49/18196?source=see_link\">",
"     ergotamine",
"    </a>",
"    preparations, alone and in combination with caffeine and other analgesics, has been used to treat migraine attacks. However, with the exception of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/3/44085?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    discussed above, the triptans have replaced ergotamine for the abortive treatment of migraine in children.",
"   </p>",
"   <p>",
"    The utility of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/49/18196?source=see_link\">",
"     ergotamine",
"    </a>",
"    is limited by side effects, especially the potentiation of nausea and vomiting, and vasospasm. Ergot preparations should",
"    <strong>",
"     not",
"    </strong>",
"    be used in basilar artery and hemiplegic migraine since they may aggravate symptoms caused by vasospasm.",
"   </p>",
"   <p>",
"    Combination drugs, consisting of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/49/18196?source=see_link\">",
"     ergotamine",
"    </a>",
"    , barbiturate, and belladonna, are",
"    <strong>",
"     not",
"    </strong>",
"    recommended for children because they are potentially habit-forming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111669477\">",
"    <span class=\"h2\">",
"     Intravenous valproate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    for the treatment of acute migraine in children is not established, and the existing evidence is limited and retrospective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. As an example, one study evaluated 31 adolescents who were treated with valproate infusions (500 to 1000 mg infused at 50",
"    <span class=\"nowrap\">",
"     mg/min)",
"    </span>",
"    one or more times for acute migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/38\">",
"     38",
"    </a>",
"    ]. Of 48 visits with adequate documentation of pain scores, headache relief considered major (51 to 80 percent pain reduction) or complete (81 to 100 percent pain reduction) was achieved in 47 percent of patients, with no or inadequate relief in 53 percent. The few prospective randomized trials evaluating intravenous valproate treatment for acute migraine in adults also suggest relatively low efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of valproic acid and its derivatives for migraine prophylaxis is discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Valproate'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROPHYLACTIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic therapy is used when headaches occur frequently or have a significant adverse impact on the child's usual activities. In general, prophylaxis is considered if headaches occur more than four times per month and require substantial medication for relief [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/27\">",
"     27",
"    </a>",
"    ]. However, parents of younger children frequently prefer symptomatic treatment to administering daily medication.",
"   </p>",
"   <p>",
"    The optimum duration of prophylactic treatment is uncertain. Our approach is to treat for six to twelve months. We then taper the drug over the course of several weeks, never stopping abruptly.",
"   </p>",
"   <p>",
"    As with acute treatments, data are limited on the effectiveness of preventive agents in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The following drugs commonly are used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cyproheptadine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/2/40996?source=see_link\">",
"     Cyproheptadine",
"    </a>",
"    (Periactin) is a histamine and serotonin antagonist with anticholinergic and calcium channel blocking properties that is used for migraine prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/44\">",
"     44",
"    </a>",
"    ]. Data for cyproheptadine are limited to a few small retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/1\">",
"     1",
"    </a>",
"    ]. One was a study of 126 children and adolescents who received various prophylactic treatments for migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/45\">",
"     45",
"    </a>",
"    ]. A positive response, defined as an overall decrease in headache frequency and intensity plus acceptability of the agent, occurred with cyproheptadine in 25 of 30 (83 percent) children. Headache frequency decreased with cyproheptadine (2 to 8 mg daily) from 8.4 to 3.7 headaches per month. In an earlier retrospective review of 12 children with abdominal migraine treated with prophylactic cyproheptadine, pain ceased in four, became milder and less frequent in six, and had no effect in two [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appetite stimulation with weight gain is a common side effect and tends to limit use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/2/40996?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    in older children. Somnolence occurs, but is less common when the dose is slowly increased and medication is administered only at night. Anticholinergic toxicity is rare and has been reported in a single child receiving therapeutic doses of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    I sometimes use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/2/40996?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    (4 to 12 mg per day) for prophylaxis in the younger child. In my experience, a single dose at bedtime helps to avoid daytime sleepiness and appears to be as effective as two or three daytime doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"     Propranolol",
"    </a>",
"    is a commonly used prophylactic treatment for children with migraine, primarily based upon evidence of its effectiveness for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H5#H5\">",
"     \"Preventive treatment of migraine in adults\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, few placebo-controlled trials have evaluated beta blockers for migraine prevention in children, and the available evidence is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], although dosing schedules have not been evaluated systematically. In a double-blind crossover trial of 39 children, the frequency, severity, and duration of headaches were similar with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/49\">",
"     49",
"    </a>",
"    ]. In another report, self-hypnosis was superior to propranolol in a dose of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/50\">",
"     50",
"    </a>",
"    ]. However, in a third study, propranolol (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) provided effective prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"     Propranolol",
"    </a>",
"    prophylaxis may be effective for abdominal migraine. In a retrospective review of 24 affected children treated with propranolol, pain ceased in 18, became milder and less frequent in 2, and had no effect in 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    I usually begin",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    in a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in three divided doses, with a maximum dose of 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Heart rate and orthostatic blood pressure should be monitored every three months or after increasing the dose. The heart rate should be &gt;60 bpm after one minute of exercise. This drug often is discontinued by children who participate in strenuous physical activities.",
"   </p>",
"   <p>",
"    Beta blockers are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in children with asthma. They should be used with caution in patients with a history of depression, diabetes, or orthostatic hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Valproate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, valproic acid and its derivatives (divalproex sodium and sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    ) are more effective than placebo for reducing the frequency of migraine attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H9#H9\">",
"     \"Preventive treatment of migraine in adults\", section on 'Anticonvulsants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Divalproex sodium may also be effective in children, but data are limited. In the only pediatric randomized trial identified in a 2013 meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/2\">",
"     2",
"    </a>",
"    ], 300 adolescents (age 12 to 17 years) were randomly assigned to treatment with extended release divalproex sodium (250 mg, 500 mg, or 1000 mg once daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/52\">",
"     52",
"    </a>",
"    ]. At 12 weeks, there was no significant difference between any of the active treatment groups and placebo for reducing the migraine headache rate.",
"   </p>",
"   <p>",
"    In this trial, adverse events associated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    use in children included upper respiratory tract infection, nausea, nasopharyngitis weight gain, and gastrointestinal upset [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/52\">",
"     52",
"    </a>",
"    ]. Other side effects in children may include somnolence, dizziness, tremor, transient hair loss, elevated serum liver enzyme and ammonia levels, and polycystic ovary syndrome. Valproate should be used cautiously in children younger than five years of age because of potential hepatotoxicity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     Valproate",
"    </a>",
"    has teratogenic effects and is associated with neural tube, cardiac, skeletal, and other defects, as well as a characteristic pattern of dysmorphic facial features. In adolescent females at risk for pregnancy,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    also should be given, based upon the recommendations for valproate treatment of epilepsy during pregnancy: women on valproate who are planning to become pregnant should receive daily folic acid supplementation (4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    prior to conception and throughout the first trimester. For all other sexually active women of child bearing potential, a lower folic acid supplement (0.4 to 0.8",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of epilepsy and pregnancy\", section on 'Folic acid supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     Valproate",
"    </a>",
"    is started in a dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in two divided doses. The dose can be increased in increments of 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to a maximum dose of 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Liver function tests and complete blood count should be monitored every two to three months during treatment. Thrombocytopenia may occur at higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/53\">",
"     53",
"    </a>",
"    ]. Serum valproic acid concentration should be monitored every three to six months to document compliance and to avoid toxic effects. A therapeutic concentration for migraine has not been established. A reasonable therapeutic range is thought to be 50 to 100",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Some patients tolerate levels up to 150",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    However, levels greater than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    should be monitored closely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2013 meta-analysis concluded that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    is more effective than placebo for episodic migraine (difference in headaches per month, &minus;0.71, 95% CI &minus;1.19 to &minus;0.24) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/2\">",
"     2",
"    </a>",
"    ], based upon limited evidence from two placebo controlled trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trial, 162 children (age 6 to 15 years) with migraine were randomly assigned in a 2:1 ratio to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"       topiramate",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/54\">",
"       54",
"      </a>",
"      ]. Topiramate was started at 15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and titrated over eight weeks to 2 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily, or the maximum tolerated dose of 200 mg daily, whichever was less. By intention-to-treat analysis at the end of the 12 week double-blind phase, the primary outcome measure (mean reduction of monthly migraine headache days) was greater for topiramate than placebo (2.6 versus 2.0), but the difference between the groups was statistically nonsignificant. However, topiramate resulted in significant improvement on some of the secondary outcome measures.",
"     </li>",
"     <li>",
"      In the second trial, 103 children (age 12 to 17 years) with migraine headache were randomly assigned in a 1:1:1 ratio to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"       topiramate",
"      </a>",
"      100 mg daily, topiramate 50 mg daily, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/55\">",
"       55",
"      </a>",
"      ]. By intention-to-treat analysis at 12 weeks, there was a statistically significant reduction in the primary outcome measure, the monthly migraine attack rate, for the topiramate 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      group (72 percent, versus 44 percent for the placebo group), while the reduction in attack rate for the 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      topiramate treatment group did not differ from placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"     Topiramate",
"    </a>",
"    treatment was generally well-tolerated in these trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, there was a higher incidence of anorexia, upper respiratory tract infections, weight loss, gastroenteritis, paresthesia, and somnolence with topiramate than with placebo in one or both trials. Topiramate may also cause cognitive impairment and concentration difficulty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several additional anticonvulsant drugs are sometime used for migraine prophylaxis in children, although there are no high-quality data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"       Gabapentin",
"      </a>",
"      treatment, in a retrospective study, was associated with a &gt;50 percent decrease in headache frequency and duration in 15 of 18 children (83 percent) 6 to 17 years old [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/0/25608?source=see_link\">",
"       Levetiracetam",
"      </a>",
"      (125 to 250 mg twice a day) was evaluated in a retrospective study of 19 patients (mean age 12 years) treated for a mean duration of 4 months [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/57\">",
"       57",
"      </a>",
"      ]. The mean headache frequency was significantly reduced from baseline to follow up (6.3 to 1.7 headaches per month), and migraine attacks ceased for 52 percent of children during treatment. Levetiracetam was discontinued in 10.5 percent because of side effects including somnolence, dizziness, and irritability.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"       Phenobarbital",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      have been considered effective for childhood migraine, based upon clinical experience [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Amitriptyline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricyclic antidepressants are used commonly for migraine prophylaxis in children. Similar to other preventive therapy, studies of these drugs are limited in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], and treatment is supported by data in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H8#H8\">",
"     \"Preventive treatment of migraine in adults\", section on 'Antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/32/7687?source=see_link\">",
"     Amitriptyline",
"    </a>",
"    is used most often in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/59\">",
"     59",
"    </a>",
"    ]. However, the effective dose has not been established, and recommended doses vary. In one report, 192 children with more than three headaches per month were treated with amitriptyline in a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/60\">",
"     60",
"    </a>",
"    ]. Of these, 84 percent reported improvement. Treatment reduced headache frequency (17 to 9 per month), severity (6.8 to 5.1 on a 10-point pain scale), and duration (11.5 to 6.3 hours). Side effects were reported as minimal but were not specified.",
"   </p>",
"   <p>",
"    Clinical experience suggests that a single daily 5 mg oral dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/32/7687?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , given at night, often is effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/61\">",
"     61",
"    </a>",
"    ]. If frequent headaches persist, the dose is advanced slowly by 5 mg increments, with at least two weeks between changes. The dose rarely should exceed 60 mg. Nonspecific electrocardiographic changes and changes in atrioventricular conduction may occur. Thus, an electrocardiogram should be obtained before using higher doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/26/38310?source=see_link\">",
"     Nortriptyline",
"    </a>",
"    is a tricyclic antidepressant and an alternative to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/32/7687?source=see_link\">",
"     amitriptyline",
"    </a>",
"    . The initial dose is 10 mg given once daily at night [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/61\">",
"     61",
"    </a>",
"    ]. No randomized controlled trial data are available for this agent in treatment of childhood and adolescent migraine.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/744?source=see_link\">",
"     Trazodone",
"    </a>",
"    is a triazolopyridine antidepressant. In a trial of 35 children age 7 to 18 years, both the trazodone and placebo groups had significant reduction in migraine frequency and duration during the first crossover phase, and the trazodone group had \"significant further improvement\" in migraine frequency and duration compared with placebo during the second crossover phase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/62\">",
"     62",
"    </a>",
"    ]. No side effects were observed in either group.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/15/40181?source=see_link\">",
"     Pizotifen",
"    </a>",
"    is a serotonin blocking agent that is unavailable in the United States. In a randomized trial of 47 children, pizotifen treatment was no better than placebo in reducing headache frequency or duration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Flunarizine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium channel blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34484?source=see_link\">",
"     flunarizine",
"    </a>",
"    may be effective for treating pediatric migraine, but as with other medications for pediatric migraine, there are few randomized trials. In the largest placebo-controlled trial, with 63 children, treatment with flunarizine 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was associated with a significant reduction in headache frequency and with decreased average headache duration compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/64\">",
"     64",
"    </a>",
"    ]. Weight gain and drowsiness were common side effects with flunarizine.",
"   </p>",
"   <p>",
"    Guidelines published in 2004 concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34484?source=see_link\">",
"     flunarizine",
"    </a>",
"    is probably effective for preventive therapy of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/1\">",
"     1",
"    </a>",
"    ], and a similar conclusion was reached in a 2003 systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/65\">",
"     65",
"    </a>",
"    ]. However, with no new randomized trials in the interim, a 2013 meta-analysis evaluated the small trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/64\">",
"     64",
"    </a>",
"    ] along with an earlier small trial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/66\">",
"     66",
"    </a>",
"    ] and found that the degree of improvement with flunarizine compared with placebo just missed statistical significance (difference in headaches per month, &minus;2.27, 95% CI &minus;4.65 to +0.11) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34484?source=see_link\">",
"     Flunarizine",
"    </a>",
"    is unavailable in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Biofeedback and relaxation techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biofeedback training and relaxation techniques may be beneficial in reducing headache symptoms. This was illustrated by two studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 18 children with migraine were randomly assigned to relaxation-response training and pain behavior management with or without electromyographic biofeedback for 11 weeks or no intervention. Headache symptoms were significantly reduced in both treatment groups compared to control [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/67\">",
"       67",
"      </a>",
"      ]. The effect was maintained for one year after treatment ended.",
"     </li>",
"     <li>",
"      In a trial in Germany, 43 children with migraine were assigned randomly to stress management training with either progressive relaxation or cephalic vasomotor feedback for six weeks or to treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/11/15544?source=see_link\">",
"       metoprolol",
"      </a>",
"      (a beta-blocker) for 10 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/68\">",
"       68",
"      </a>",
"      ]. Reduction in the headache index (a measure of frequency and intensity of headache episodes) was greatest with relaxation and stress management training, next with cephalic vasomotor feedback and stress management training, and least with metoprolol. Clinical improvement persisted through follow-up at eight months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although behavioral techniques appear to be effective, several issues limit their widespread use. These include restricted availability, high cost that may not be covered by health insurance, and the failure of children to practice these techniques consistently [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Menstrual migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual migraine (also called menstrually associated migraine or catamenial migraine) is defined as migraine headache that occurs in close temporal relationship to the onset of menstruation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H20#H20\">",
"     \"Classification of migraine in children\", section on 'Menstrual migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short-term preventive therapy during the perimenstrual period may be useful for girls who have menstrual migraine that occurs on a predictable schedule. This treatment strategy is called \"mini-prophylaxis\" and usually consists of preventive medication started one or two days prior to the expected onset of headache and continued for the expected duration of the headache.",
"   </p>",
"   <p>",
"    NSAIDs are often used for mini-prophylaxis.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/61/27608?source=see_link\">",
"     Naproxen",
"    </a>",
"    sodium 550 mg twice daily during the perimenstrual period is one commonly used regimen. Placebo-controlled trials have demonstrated that triptans are effective for menstrual migraine, but most of the data come from adults.",
"   </p>",
"   <p>",
"    The treatment of menstrual migraine is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=see_link&amp;anchor=H4#H4\">",
"     \"Estrogen-associated migraine\", section on 'Menstrual migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with migraine have a relatively good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. Long-term follow-up studies suggest that many patients improve with time, although others continue to have headaches or relapse after a headache-free period.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from Italy, 81 patients with migraine (onset at 6 to 54 years of age) were followed for 10 to 20 years [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/70\">",
"       70",
"      </a>",
"      ]. The frequency of headaches decreased considerably in 54.4 percent of cases and increased in 25 percent. Headaches became less or more severe in 36.2 and 5.5 percent, respectively, and resolved completely in 11.1 percent.",
"     </li>",
"     <li>",
"      A longitudinal study from Sweden followed 73 children who had severe migraine with onset at approximately six years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/69,71\">",
"       69,71",
"      </a>",
"      ]. Although 23 percent were headache-free before the age of 25 years, more than one-half reported migraines at ages 30 and 50 years. Girls were more likely to relapse than were boys.",
"     </li>",
"     <li>",
"      A 10-year follow-up study was conducted of 181 children with migraine in Spain [",
"      <a class=\"abstract\" href=\"UTD.htm?18/3/18490/abstract/72\">",
"       72",
"      </a>",
"      ]. Onset occurred before six years or at six to ten years of age in 24 and 57 percent, respectively. The clinical course was favorable in 88 percent of patients; the remainder received prophylactic treatment. In this series, in contrast to others, an unfavorable course was associated with earlier onset of migraine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/9/33938?source=see_link\">",
"       \"Patient information: Migraine headaches in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/29/27090?source=see_link\">",
"       \"Patient information: Headaches in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=see_link\">",
"       \"Patient information: Headache in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the paucity of definitive data in children, the management of migraine headache varies among clinicians. The following recommendations represent our suggested approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86795965\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient and family should be educated about the management of migraine headache. A headache calendar should be maintained in order to identify triggering factors and to document response to treatment. Precipitating factors, if identified, should be avoided. When symptoms develop, the child should rest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sleep in a quiet dark room with a cool cloth applied to the forehead. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Abortive treatment recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with acute migraine headache, we suggest initial abortive treatment with an analgesic, either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , both of which have proven efficacy for migraine in children in randomized, controlled trials. The initial choice depends upon individual preference. If the patient does not respond to one, the other can be tried. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Abortive treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      is given in an initial dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      This dose may be repeated in four to six hours if needed. No more than four doses should be given in 24 hours (maximum daily dose 40",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      Alternatively,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      can be given in a dose of 10 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (usually as one or two 325 mg tablets), with a maximum dose of 1000 mg. This may be repeated in two to four hours if symptoms persist but should not exceed three doses in 24 hours. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'NSAIDs and acetaminophen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An antiemetic is given to children with nausea and vomiting. We prefer",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"       promethazine",
"      </a>",
"      in a dose of 0.25 to 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      rectally and repeat as needed at intervals of four to six hours. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antiemetics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children who have acute migraine headache without vomiting that is refractory to analgesics, we suggest initial treatment with oral triptans. Our preferred agent is oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"       sumatriptan",
"      </a>",
"      starting at 25 mg, with a maximum dose of 50 mg. For children who do not respond to oral sumatriptan, alternatives include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/24/8581?source=see_link\">",
"       rizatriptan",
"      </a>",
"      (5 mg wafer),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      (2.5 or 5 mg), and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32388?source=see_link\">",
"       almotriptan",
"      </a>",
"      (6.25 or 12.5 mg). For adolescents with migraine who have early nausea or vomiting, we prefer the orally disintegrating tablet formulations of zolmitriptan and rizatriptan. (See",
"      <a class=\"local\" href=\"#H27076669\">",
"       'Oral triptans'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children and adolescents who have acute migraine headache without vomiting who do not respond to monotherapy with other abortive migraine medications, we suggest treatment with combination of oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"       sumatriptan",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/61/27608?source=see_link\">",
"       naproxen",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H207323099\">",
"       'Sumatriptan plus naproxen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children at least five years of age, if analgesics do not provide relief or if persistent vomiting precludes the use of oral medications, we suggest a trial of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"       sumatriptan",
"      </a>",
"      nasal spray due to its proven efficacy in randomized, controlled trials in adolescents. In addition, it is generally more tolerable to children than an injection. We prefer to start with 5 mg and repeat once in four to six hours if initially effective but the headache returns. If there is no benefit, 10 mg nasal spray (two 5 mg units given together) may be tried. We suggest similar doses of nasal spray in older children, with a maximum daily dose of 20 mg. One limitation to nasal sumatriptan is the associated bad taste, which limits its acceptability in children. This problem can be mitigated by having children suck on a piece of hard candy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nasal sumatriptan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As alternative,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      5 mg nasal spray can be used, given the randomized clinical trial evidence cited earlier that this agent is safe and effective for the treatment of migraine in adolescents. In the clinical experience of some experts, zolmitriptan nasal spray has a less objectionable taste than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"       sumatriptan",
"      </a>",
"      nasal spray. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nasal zolmitriptan'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Prophylactic treatment recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic treatment is used when headaches are frequent (more than four times per month) or if severe and prolonged headache results in frequent school absences or prevents important daily activities. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Prophylactic treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the absence of better evidence from clinical trials, we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children younger than six years of age, we suggest",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/2/40996?source=see_link\">",
"       cyproheptadine",
"      </a>",
"      (Periactin) in a dose of 4 to 12 mg per day, given orally once at bedtime. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cyproheptadine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In older children, we suggest",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"       propranolol",
"      </a>",
"      in a starting dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in three divided doses, with a maximum dose of 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Heart rate and orthostatic blood pressure should be monitored periodically. The heart rate should be &gt;60 bpm after one minute of exercise. This drug is often discontinued by children who participate in strenuous physical activities. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"       propranolol",
"      </a>",
"      is not well tolerated, we suggest",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"       valproate",
"      </a>",
"      for prophylaxis. Valproate is given primarily to boys older than five years of age. We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using this drug in adolescent females because of concerns about weight gain and polycystic ovary syndrome. Prior to use, the potential side effects are discussed with the parents and child. Valproate is started in a dose of 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in two to three divided doses orally. The dose can be increased in increments of 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to a maximum dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Serum valproic acid concentration should be monitored every three to six months to document compliance and to help adjust doses to avoid toxicity. Complete blood counts, liver function tests, and electrolyte concentrations also should be monitored periodically. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Valproate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is a mixed headache disorder or possible depression, we suggest",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/32/7687?source=see_link\">",
"       amitriptyline",
"      </a>",
"      , starting with a single daily 5 mg oral dose, given at night. If frequent headaches persist, the dose is advanced slowly by 5 mg increments, with at least two weeks between changes. The dose should rarely exceed 60 mg daily. An electrocardiogram should be obtained before using higher doses. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Amitriptyline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Where available outside the United States,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34484?source=see_link\">",
"       flunarizine",
"      </a>",
"      5 mg daily is a reasonable first line agent, but weight gain and drowsiness are significant side effects. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Flunarizine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biofeedback and relaxation techniques may be helpful. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Biofeedback and relaxation techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/1\">",
"      Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/2\">",
"      El-Chammas K, Keyes J, Thompson N, et al. Pharmacologic Treatment of Pediatric Headaches: A Meta-analysis. JAMA Pediatr 2013; 167:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/3\">",
"      O'Brien HL, Kabbouche MA, Hershey AD. Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother 2012; 13:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/4\">",
"      Mets&auml;honkala L, Sillanp&auml;&auml; M, Tuominen J. Headache diary in the diagnosis of childhood migraine. Headache 1997; 37:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/5\">",
"      Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002; 59:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/6\">",
"      Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/7\">",
"      Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004; 56:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/8\">",
"      Eiland LS, Hunt MO. The use of triptans for pediatric migraines. Paediatr Drugs 2010; 12:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/9\">",
"      Rolan PE. Drug interactions with triptans : which are clinically significant? CNS Drugs 2012; 26:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/10\">",
"      Evans RW. Concomitant triptan and SSRI or SNRI use: what is the risk for serotonin syndrome? Headache 2008; 48:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/11\">",
"      Wenzel RG, Tepper S, Korab WE, Freitag F. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted? Ann Pharmacother 2008; 42:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/12\">",
"      Linder SL, Mathew NT, Cady RK, et al. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache 2008; 48:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/13\">",
"      Winner P, Lewis D, Visser WH, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 2002; 42:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/14\">",
"      Ahonen K, H&auml;m&auml;l&auml;inen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology 2006; 67:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/15\">",
"      Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology 2006; 67:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/16\">",
"      Linder SL, Dowson AJ. Zolmitriptan provides effective migraine relief in adolescents. Int J Clin Pract 2000; 54:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/17\">",
"      H&auml;m&auml;l&auml;inen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Neurology 1997; 48:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/18\">",
"      Ueberall MA, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children. Neurology 1999; 52:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/19\">",
"      Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000; 106:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/20\">",
"      Ahonen K, H&auml;m&auml;l&auml;inen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. Neurology 2004; 62:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/21\">",
"      Damen L, Bruijn JK, Verhagen AP, et al. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics 2005; 116:e295.",
"     </a>",
"    </li>",
"    <li>",
"     Winner, P, Rothner, AD. Headaches in children and adolescents. BC Decker, Hamilton, ON 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/23\">",
"      MacDonald JT. Treatment of juvenile migraine with subcutaneous sumatriptan. Headache 1994; 34:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/24\">",
"      Linder SL. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice. Headache 1996; 36:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/25\">",
"      Lewis DW, Winner P, Hershey AD, et al. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics 2007; 120:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/26\">",
"      H&auml;m&auml;l&auml;inen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology 1997; 48:103.",
"     </a>",
"    </li>",
"    <li>",
"     Prensky, AL. Headache. In: Oski's Pediatrics. Principles and Practice, 4th ed, McMillan, JA, Feigin, RD, DeAngelis, C, Jones, MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p. 2388.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/28\">",
"      Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med 2004; 43:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/29\">",
"      Derosier FJ, Lewis D, Hershey AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics 2012; 129:e1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/30\">",
"      Polizos P, Engelhardt DM. Dyskinetic phenomena in children treated with psychotropic medications. Psychopharmacol Bull 1978; 14:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/31\">",
"      Kabbouche MA, Vockell AL, LeCates SL, et al. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics 2001; 107:E62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/32\">",
"      Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993; 22:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/33\">",
"      Leopold NA. Prolonged metoclopramide-induced dyskinetic reaction. Neurology 1984; 34:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/34\">",
"      Cowan AN. Acute dystonic reaction to Maxolon (metoclopramide). Med J Aust 1982; 2:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/35\">",
"      Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/36\">",
"      Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache 2009; 49:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/37\">",
"      Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache 1994; 34:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/38\">",
"      Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache 2005; 45:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/39\">",
"      Avraham SB, Har-Gil M, Watemberg N. Acute confusional migraine in an adolescent: response to intravenous valproate. Pediatrics 2010; 125:e956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/40\">",
"      Gelfand AA, Goadsby PJ. Treatment of pediatric migraine in the emergency room. Pediatr Neurol 2012; 47:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/41\">",
"      Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001; 41:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/42\">",
"      Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med 2003; 41:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/43\">",
"      Leniger T, Pageler L, Stude P, et al. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005; 45:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/44\">",
"      Bille B, Ludvigsson J, Sanner G. Prophylaxis of migraine in children. Headache 1977; 17:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/45\">",
"      Lewis DW, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. Headache 2004; 44:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/46\">",
"      Worawattanakul M, Rhoads JM, Lichtman SN, Ulshen MH. Abdominal migraine: prophylactic treatment and follow-up. J Pediatr Gastroenterol Nutr 1999; 28:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/47\">",
"      Watemberg NM, Roth KS, Alehan FK, Epstein CE. Central anticholinergic syndrome on therapeutic doses of cyproheptadine. Pediatrics 1999; 103:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/48\">",
"      Annequin D, Tourniaire B, Massiou H. Migraine and headache in childhood and adolescence. Pediatr Clin North Am 2000; 47:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/49\">",
"      Forsythe WI, Gillies D, Sills MA. Propanolol ('Inderal') in the treatment of childhood migraine. Dev Med Child Neurol 1984; 26:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/50\">",
"      Olness K, MacDonald JT, Uden DL. Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine. Pediatrics 1987; 79:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/51\">",
"      Ludvigsson J. Propranolol used in prophylaxis of migraine in children. Acta Neurol Scand 1974; 50:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/52\">",
"      Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache 2008; 48:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/53\">",
"      Loiseau P. Sodium valproate, platelet dysfunction, and bleeding. Epilepsia 1981; 22:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/54\">",
"      Winner P, Pearlman EM, Linder SL, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/55\">",
"      Lewis D, Winner P, Saper J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 2009; 123:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/56\">",
"      Belman, A, Milazo, M, Savatic, M, Gabis, L. Gabapentin for migraine prophylaxis in children (abstract). Ann Neurol 2001; 50:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/57\">",
"      Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache 2004; 44:238.",
"     </a>",
"    </li>",
"    <li>",
"     Barlow, CF. Headaches and migraine in childhood (Clinics in Developmental Medicine). Lippincott, Williams and Wilkins, Philadelphia 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/59\">",
"      Prensky A. Childhood Migraine Headache Syndromes. Curr Treat Options Neurol 2001; 3:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/60\">",
"      Hershey AD, Powers SW, Bentti AL, Degrauw TJ. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache 2000; 40:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/61\">",
"      Winner PK. Headaches in children. When is a complete diagnostic workup indicated? Postgrad Med 1997; 101:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/62\">",
"      Battistella PA, Ruffilli R, Cernetti R, et al. A placebo-controlled crossover trial using trazodone in pediatric migraine. Headache 1993; 33:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/63\">",
"      Gillies D, Sills M, Forsythe I. Pizotifen (Sanomigran) in childhood migraine. A double-blind controlled trial. Eur Neurol 1986; 25:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/64\">",
"      Sorge F, De Simone R, Marano E, et al. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study. Cephalalgia 1988; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/65\">",
"      Victor S, Ryan SW. Drugs for preventing migraine headaches in children. Cochrane Database Syst Rev 2003; :CD002761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/66\">",
"      Garaizar C, Prats JM, Zuazo E. [Response to prophylactic treatment of benign headache in children]. Rev Neurol 1998; 26:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/67\">",
"      Fentress DW, Masek BJ, Mehegan JE, Benson H. Biofeedback and relaxation-response training in the treatment of pediatric migraine. Dev Med Child Neurol 1986; 28:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/68\">",
"      Sartory G, M&uuml;ller B, Metsch J, Pothmann R. A comparison of psychological and pharmacological treatment of pediatric migraine. Behav Res Ther 1998; 36:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/69\">",
"      Bille B. Migraine in childhood and its prognosis. Cephalalgia 1981; 1:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/70\">",
"      Cologno D, Torelli P, Manzoni GC. Migraine with aura: a review of 81 patients at 10-20 years' follow-up. Cephalalgia 1998; 18:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/71\">",
"      Bille B. A 40-year follow-up of school children with migraine. Cephalalgia 1997; 17:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/72\">",
"      Hernandez-Latorre MA, Roig M. Natural history of migraine in childhood. Cephalalgia 2000; 20:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/3/18490/abstract/73\">",
"      Monastero R, Camarda C, Pipia C, Camarda R. Prognosis of migraine headaches in adolescents: a 10-year follow-up study. Neurology 2006; 67:1353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6168 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18490=[""].join("\n");
var outline_f18_3_18490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ABORTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Triptans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27076669\">",
"      - Oral triptans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Nasal sumatriptan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Subcutaneous sumatriptan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nasal zolmitriptan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NSAIDs and acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H207323099\">",
"      Sumatriptan plus naproxen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antiemetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dihydroergotamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other ergotamine preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111669477\">",
"      Intravenous valproate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROPHYLACTIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cyproheptadine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Valproate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Topiramate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Amitriptyline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Flunarizine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Biofeedback and relaxation techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Menstrual migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86795965\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Abortive treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Prophylactic treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=related_link\">",
"      Approach to the child with headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=related_link\">",
"      Estrogen-associated migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=related_link\">",
"      Management of epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=related_link\">",
"      Medication overuse headache: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=related_link\">",
"      Medication overuse headache: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8600?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=related_link\">",
"      Patient information: Headache in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/29/27090?source=related_link\">",
"      Patient information: Headaches in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/9/33938?source=related_link\">",
"      Patient information: Migraine headaches in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_3_18491="Sensitivity of tests for MG";
var content_f18_3_18491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approximate sensitivity of the confirmatory tests for myasthenia gravis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generalized myasthenia percent positive",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ocular myasthenia percent positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Acetylcholine receptor antibodies",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        80-90",
"       </td>",
"       <td class=\"centered\">",
"        40-55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         MuSK antibodies (in AChR Ab negative patients)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        40-50",
"       </td>",
"       <td class=\"centered\">",
"        &lt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Repetitive nerve stimulation",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Single fiber electromyography",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        92-99",
"       </td>",
"       <td class=\"centered\">",
"        85-95",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18491=[""].join("\n");
var outline_f18_3_18491=null;
var title_f18_3_18492="Regulation insulin release";
var content_f18_3_18492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Regulation of insulin release",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Factors that stimulate insulin release",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose, mannose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leucine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vagal stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfonylurea drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Factors that amplify glucose-induced insulin release",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Enteric hormones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glucagon-like peptide 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gastric inhibitory peptide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cholecystokinin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Secretin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gastrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neural amplifiers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Beta-adrenergic stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Amino acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Arginine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Prostaglandin E2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inhibitors of insulin release",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neural",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alpha-adrenergic effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Humoral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Somatostatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diazoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vinblastine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Colchicine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Masharani U, Karam JH. Pancreatic hormones and diabetes mellitus. In: Basic and Clinical Endocrinology, 6th ed, Greenspan, FS, Gardner, DC (eds), McGraw-Hill, 2001. p. 627. Copyright &copy; 2001. McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18492=[""].join("\n");
var outline_f18_3_18492=null;
var title_f18_3_18493="Differential diagnosis of excessive daytime sleepiness";
var content_f18_3_18493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F86811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F86811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of excessive daytime sleepiniess",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Insufficient sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep deprivation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Environmental intrusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sleep disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstructive sleep apnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central sleep apnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep-related hypoventilation/hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Circadian rhythm sleep disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Delayed sleep phase disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Advanced sleep phase disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Jet lag",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Shift work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restless legs syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periodic limb movement disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disorders that cause insomnia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypersomnias of central origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Narcolepsy with or without cataplexy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent hypersomnia (including Kleine-Levin syndrome, mentrual-related hypersomnia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic hypersomnia with or without long sleep time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neurodegenerative disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parkinson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dementia with Lewy bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alzheimer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Multiple system atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myotonic dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyotrophic lateral sclerosis (via sleep-related breathing disorders)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Structural lesions affecting thalamus, hypothalamus or brainstem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-traumatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalitis lethargica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral trypanosomiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medical and genetic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        End-stage renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Niemann-Pick Type C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prader-Willi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moebius syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fragile X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychiatric disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Substance abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Narcotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prescription opioid abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Stimulant withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychogenic sleepiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonbenzodiazepine sedatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioid analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta blockers (lipophilic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sedative antidepressants",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18493=[""].join("\n");
var outline_f18_3_18493=null;
var title_f18_3_18494="Diagnosis of acromegaly";
var content_f18_3_18494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for the diagnosis of acromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Melmed S, Anterior pituitary. In: Current Practice of Medicine, Korenman S (Ed), 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18494=[""].join("\n");
var outline_f18_3_18494=null;
var title_f18_3_18495="Lifestyle changes in CVS";
var content_f18_3_18495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77478%7EGAST%2F68579%7EGAST%2F78562%7EGAST%2F59920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77478%7EGAST%2F68579%7EGAST%2F78562%7EGAST%2F59920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lifestyle changes in CVS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lifestyle changes (for one to two months or one to two cycles)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Reassurance",
"        </strong>",
"        (eg, episodes are not self-induced) and anticipatory guidance (eg, natural history)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Avoidance of triggers",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Keep a \"vomiting diary\" of potential precipitating factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid fasting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recognize the potential role of excitement as a trigger (eg, downplay big events)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maintain good sleep hygiene (eg, avoid sleep deprivation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid triggering foods: chocolate, cheese, monosodium glutamate, antigenic foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid excessive energy output",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Supplemental carbohydrate: for fasting-induced episodes",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide fruit juices, other sugar-containing drinks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide extra snacks between meals, before exertion, or at bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Migraine headache lifestyle interventions",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regular aerobic exercise (avoid overexercising)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regular meal schedules (ie, avoid skipping meals)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderation in consuming or avoidance of caffeine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prophylactic or preventive medications* in CVS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children 2 to 5 years old",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Antihistamines: cyproheptadine (first choice) and pizotifen (available in UK, Canada)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyproheptadine 0.25-0.5 mg/kg/day orally divided twice daily or three times daily (maximum 12 mg per 24 hours). (Available in 2 mg/5 mL liquid).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: increased appetite, weight gain, sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternatives: pizotifen (available in UK, Canada)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Beta-blockers: propranolol (second choice)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Propranolol 0.25-1 mg/kg/day orally divided twice daily or three times daily, most often 10 mg twice daily or three times daily. Initiate at 0.25 mg/kg/day and increase every 1-4 weeks in increments of 0.25 mg/kg/day as needed and tolerated. (&lt;35 kg maximum 60 mg per 24 hours. &ge;35 kg maximum 120 mg per 24 hours). (Available in liquid).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Monitor: resting heart rate maintain &ge;60 bpm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: lethargy, reduced exercise intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Contraindications: asthma, diabetes, heart disease, depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discontinuation: tapered for 1-2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children older than 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tricyclic antidepressants: amitriptyline (first choice)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amitriptyline begin at 0.25-0.5 mg/kg/day orally at bedtime, increase every 1-4 weeks as needed and tolerated by 5-10 mg, until 1-1.5 mg/kg/day (maximum 75 mg per 24 hours). (For dose &gt;1 mg/kg/day, divide twice daily).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Monitor: &radic;EKG QT",
"        <sub>",
"         c",
"        </sub>",
"        interval before starting and 10 days after peak dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: constipation, sedation, arrhythmia, behavioral changes (especially in young children)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternatives: nortriptyline",
"        <sup>",
"         &bull;",
"        </sup>",
"        (available in 10 mg/5 mL liquid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Beta-blockers: propranolol (second choice) - see above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Anticonvulsants: phenobarbital",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenobarbital 2 mg/kg/day orally administered at bedtime (maximum 40 mg per 24 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: sedation, cognitive impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternatives: topiramate, valproic acid, gabapentin, levetiracetam - consult Pediatric neurologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Supplements",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L-carnitine 50-100 mg/kg/day orally divided twice daily or three times daily (maximum 1 g three times daily)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coenzyme Q",
"        <sub>",
"         10",
"        </sub>",
"        10 mg/kg/day orally divided twice daily or three times daily (maximum 100 mg three times daily)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: diarrhea, fishy body odor (for L-carnitine)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All medication recommendations are made for off-label use.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Limited or no published experience regarding efficacy.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Supportive and abortive treatment approaches in CVS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supportive care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Fluid, electrolyte and nutritional management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infuse 10% dextrose, 0.45% (half normal) saline solution and potassium chloride as appropriate at 1.5 times maintenance fluid rates OR through a Y-connector 10% dextrose infusion at one times maintenance and normal saline at 0.5 times maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If no enteral intake for 3-5 days, initiate peripheral parenteral nutrition with 1.5 g of amino acids/kg/day and energy units above the catabolic threshold of 55-70 kcal/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Antiemetic (5HT",
"        <sub>",
"         3",
"        </sub>",
"        antagonist) agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ondansetron 0.3-0.4 mg/kg/dose intravenously every 4-6 hours (maximum 20 mg per dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternatives: granisetron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Sedatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diphenhydramine 1-1.25 mg/kg/dose intravenously every 6 hours (maximum 50 mg per dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lorazepam 0.05-0.1 mg/kg/dose intravenously every 6 hours (maximum 2 mg per dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: respiratory depression, hallucinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Chlorpromazine 0.5-1 mg/kg/dose intravenously every 6 hours + diphenhydramine (see above) intravenously:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &lt;5 years or &lt;23 kg maximum 10 mg per dose, 40 mg per 24 hours chlorpromazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &gt;5 years or &ge;23 kg maximum 18 mg per dose, 75 mg per 24 hours chlorpromazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: dystonic reactions with chlorpromazine alone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Analgesics (nonsteroidal and narcotic) agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ketorolac 0.4-1 mg/kg intravenously every 6 hours x 48 hours (maximum 30 mg per dose, maximum 120 mg per 24 hours); avoid in renal insufficiency or dehydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: gastrointestinal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternatives: narcotics, intravenous morphine or fentanyl by bolus or by patient-control infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Treatment of specific signs and symptoms: epigastric pain, diarrhea, and hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epigastric pain: acid suppression by H",
"        <sub>",
"         2",
"        </sub>",
"        RAs or PPIs, (eg, intravenous ranitidine, pantoprazole)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diarrhea: antidiarrheals (eg, loperamide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypertension: short-acting ACE inhibitors (eg, captopril)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Treatment of specific complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dehydration and electrolyte deficit: replace calculated deficits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metabolic acidosis: determine cause and treat accordingly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SIADH: restrict free water intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hematemesis: intravenous H",
"        <sub>",
"         2",
"        </sub>",
"        RAs or PPIs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weight loss: nasogastric or parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abortive care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Antimigraine (triptan) agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sumatriptan: 20 mg once intranasally as early as possible at episode onset for children 12 years and older (maximum 40 mg/24 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: neck pain/burning, coronary vasospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Contraindications: basilar artery migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recovery and refeeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Feed ad libitum when child declares episode is over",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H",
"     <sub>",
"      2",
"     </sub>",
"     RAs: histamine-2 receptor antagonists; PPIs: proton pump inhibitors; ACE: angiotensive converting enzyme; SIADH: syndrome of inappropriate antidiuretic hormone; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sample treatment protocol order sheet for a child having an acute attack of CVS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        In Emergency Department and in-hospital settings, an example of a regimen would include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Darkened, quiet room, take vital signs every 4-6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If child is dehydrated, rehydrate with initial intravenous fluid bolus of 10 mL/kg normal 0.9% saline and repeat as clinically necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infuse 10% dextrose 0.45% (half normal) saline solution with potassium chloride as appropriate at 1.5 times maintenance rates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous ondansetron 0.3 mg/kg/dose every 6 hours x 24 hours (maximum 20 mg per dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous lorazepam 0.05 mg/kg/dose every 6 hours x 24 hours (maximum 2 mg per dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If child has moderate to severe abdominal pain, intravenous ketorolac 0.5 to 1 mg/kg/dose (maximum 30 mg per dose) every 6 hours x 24 hours (avoid in renal insufficiency or prior to hydration if dehydrated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Admit child if &gt;5 percent dehydrated, no urine output &gt;12 hours, Na",
"        <sup>",
"         +",
"        </sup>",
"        &lt;130 mEq/L, anion gap &gt;18 mEq/L, or inability to stop emesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allow oral fluid intake",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_3_18495=[""].join("\n");
var outline_f18_3_18495=null;
